[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 161
1. Kwiek S, Slusarczyk W, Kukier W, Luszawski J, Bazowski P, Wolwender A, Duda I, Grzybowska K, Wójcikiewicz T: [Multimodal intraoperative electrophysiological monitoring during cerebellopontine angle tumor surgery. Benefit or loss?]. Neurol Neurochir Pol; 2003 Sep-Oct;37(5):1047-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multimodal intraoperative electrophysiological monitoring during cerebellopontine angle tumor surgery. Benefit or loss?].
  • In the Neurosurgery Department, Silesian University School of Medicine, continuous monitoring of selected neurophysiological functions of the central and peripheral nervous system was introduced in 1998 as a routine procedure in cerebellopontine angle surgery and some other operations performed in the petroclival region.
  • The paper presents results of a detailed statistical analysis of the amount of time required for preparation and for operating in 174 cerebellopontine angle tumor surgeries performed in the years 1986-2002 with (group M) and without (group BM, before the year 1998) intraoperative monitoring.
  • Subgroups distinguished according to the histological type of tumor were evaluated.
  • Out of 95 procedures performed in group M, 57 were operations of acoustic neurinoma cases, 15 meningiomas, 8 cases of epidermal cyst, and 15 other growth processes in the cerebellopontine angle region.
  • Among 79 operations in group BM, there were 57 cases of acoustic neurinoma, 4 cases of meningioma, 8 cases of epidermal cyst, and 10 of other types of neoplastic growth.
  • In group M as compared to group BM the pre-op. preparation time was found to be significantly longer in cases of the VIII-th nerve neurinoma, and of other tumors.
  • Both radicality of tumor removal and facial nerve status have clearly improved since intraoperative monitoring was introduced.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15174251.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


2. Moeckli R, Ozsahin M, Pache G, Valley JF, Mirimanoff RO, Azria D: Fetal dose reduction in head and neck radiotherapy of a pregnant woman. Z Med Phys; 2004;14(3):168-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: A pregnant woman was referred for post-operative radiotherapy of a malignant schwannoma in the head and neck region.
  • MATERIAL AND METHODS: The fetal dose resulting from radiological examinations was determined according to international protocols, that resulting from radiotherapy was calculated according to Recommendation 36 of the American Association of Physicists in Medicine (AAPM) Task Group.
  • RESULTS: The total fetal dose resulting from diagnostic and radiotherapy procedures was estimated to be 36 mGy.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15462418.001).
  • [ISSN] 0939-3889
  • [Journal-full-title] Zeitschrift für medizinische Physik
  • [ISO-abbreviation] Z Med Phys
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


3. Palmer JD, Francis JL, Pickard JD, Iannotti F: The efficacy and safety of aprotinin for hemostasis during intracranial surgery. J Neurosurg; 2003 Jun;98(6):1208-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One hundred patients with a preoperative diagnosis of intracranial meningioma or vestibular schwannoma subsequently confirmed on histological studies were included.
  • All patients were older than 18 years of age, pregnancy had been excluded, there was no history of bleeding diathesis, no previous exposure to aprotinin, and no ingestion of antiplatelet or anticoagulant medications within the 2 weeks preceding surgery.
  • Aprotinin therefore can be safely used to reduce intraoperative blood loss in patients who are not receiving anticoagulation therapy.
  • [MeSH-minor] Blood Transfusion / statistics & numerical data. Cognition / drug effects. Double-Blind Method. Drug Administration Schedule. Female. Humans. Male. Meningeal Neoplasms / surgery. Meningioma / surgery. Middle Aged. Neuropsychological Tests. Risk Factors. Treatment Outcome

  • Hazardous Substances Data Bank. APROTININ .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2005 Apr;102(4):757-8; author reply 758 [15871522.001]
  • (PMID = 12816266.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemostatics; 9087-70-1 / Aprotinin
  •  go-up   go-down


Advertisement
4. Ishimori Y, Kimura H, Uematsu H, Matsuda T, Itoh H: Dynamic T1 estimation of brain tumors using double-echo dynamic MR imaging. J Magn Reson Imaging; 2003 Jul;18(1):113-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To assess the clinical utility of a new method for real-time estimation of T1 during the first pass of contrast agent by using this method to examine brain tumors.
  • In the latter half of this sequence, changes in absolute T1 were calculated using differences in signal intensities before and after injection of contrast agent.
  • Five cases of neurinoma and seven cases of meningioma were examined.
  • Changes in T1 during the first pass of contrast agent were compared between neurinoma and meningioma.
  • Although the changes in absolute T1 during the first pass of contrast agent did not allow differentiation between the two types of tumors, the mean gradient after the first pass was statistically higher for neurinoma than for meningioma (P < 0.05; meningioma, 0.011 +/- 0.012 second(-1)/second; neurinoma, 0.034 +/- 0.020 second(-1)/second).
  • [MeSH-major] Brain Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Meningioma / diagnosis. Neurilemmoma / diagnosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12815646.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


5. Hovens CM, Kaye AH: The tumour suppressor protein NF2/merlin: the puzzle continues. J Clin Neurosci; 2001 Jan;8(1):4-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tumour suppressor protein NF2/merlin: the puzzle continues.
  • Neurofibromatosis type 2 (NF2) is a dominantly inherited disease characterized by the formation of bilateral acoustic schwannomas and other benign tumours associated with the central nervous system.
  • The NF2 protein, also known as merlin or schwannomin, is a recently cloned tumour suppressor and is mutated or inactivated in most schwannomas and meningiomas.
  • Homology analysis indicates that merlin is most closely related to members of the protein 4.1 superfamily especially ezrin, radixin and moesin, the ERM proteins.
  • ERM proteins link membrane proteins to the cytoskeleton.
  • Recent evidence of post-translational regulatory mechanisms which offer hope for new drug intervention strategies to help alleviate this debilitating disease are asses sed.
  • [MeSH-major] Membrane Proteins / metabolism. Neurofibromatosis 2 / physiopathology
  • [MeSH-minor] Animals. Calpain / genetics. Calpain / metabolism. Cytoskeleton / metabolism. Cytoskeleton / pathology. Humans. Neurofibromin 2. Protein Structure, Tertiary / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11148074.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Neurofibromin 2; EC 3.4.22.- / Calpain
  • [Number-of-references] 46
  •  go-up   go-down


6. Chang J, Klein MB: Images in clinical medicine. Ulnar-nerve schwannoma. N Engl J Med; 2002 Sep 19;347(12):903
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Images in clinical medicine. Ulnar-nerve schwannoma.
  • [MeSH-major] Neurilemmoma / pathology. Peripheral Nervous System Neoplasms / pathology. Ulnar Nerve / pathology

  • Genetic Alliance. consumer health - Schwannoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12239259.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Flaiz C, Chernoff J, Ammoun S, Peterson JR, Hanemann CO: PAK kinase regulates Rac GTPase and is a potential target in human schwannomas. Exp Neurol; 2009 Jul;218(1):137-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAK kinase regulates Rac GTPase and is a potential target in human schwannomas.
  • Merlin loss causes benign tumours of the nervous system, mainly schwannomas and meningiomas.
  • Schwannomas show enhanced Rac1 and Cdc42 activity, the p21-activated kinase 2 (PAK2) activation and increased ruffling and cell adhesion.
  • PAK has been proposed as a potential therapeutic target in schwannomas.
  • We used a novel small-molecule PAK inhibitor, IPA-3, to investigate the role of PAK activation on Rac1/Cdc42 activity, cell spreading and adhesion in human primary schwannoma and Schwann cells.
  • Accordingly, Pix-mediated Rac1 activation is decreased in IPA-3 treated schwannoma cells, indicating that PAK acts upstream of Rac.
  • We show that this Rac activation at the level of focal adhesions in schwannoma cells is essential for cell spreading and adhesion in Schwann and schwannoma cells.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-SERINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] Chem Biol. 2008 Apr;15(4):322-31 [18420139.001]
  • [Cites] Trends Cell Biol. 2002 Mar;12(3):112-20 [11859023.001]
  • [Cites] Genes Dev. 2003 May 1;17(9):1090-100 [12695331.001]
  • [Cites] Hum Mol Genet. 2003 Jun 1;12(11):1211-21 [12761036.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):352-63 [12946024.001]
  • [Cites] Annu Rev Biochem. 2003;72:743-81 [12676796.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):841-9 [14580336.001]
  • [Cites] Cancer J. 2004 Jan-Feb;10(1):20-6 [15000491.001]
  • [Cites] Cell. 1992 Aug 7;70(3):389-99 [1643657.001]
  • [Cites] Nature. 1994 Jan 6;367(6458):40-6 [8107774.001]
  • [Cites] Mol Cell. 1998 Jan;1(2):183-92 [9659915.001]
  • [Cites] Neurobiol Dis. 1998 Jul;5(1):55-64 [9702788.001]
  • [Cites] Oncogene. 1998 Oct 29;17(17):2195-209 [9811451.001]
  • [Cites] Oncogene. 2008 Apr 24;27(19):2705-15 [17998937.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5236-45 [18593924.001]
  • [Cites] Environ Toxicol Chem. 2008 Jul;27(7):1451-74 [18275256.001]
  • [Cites] Brain Pathol. 2009 Jan;19(1):27-38 [18445079.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):883-6 [11719502.001]
  • [Cites] Biochem J. 2005 Mar 1;386(Pt 2):201-14 [15548136.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):17-22 [15779232.001]
  • [Cites] Neurobiol Dis. 2005 Jun-Jul;19(1-2):1-9 [15837555.001]
  • [Cites] J Biol Chem. 2005 Nov 4;280(44):36609-15 [16129686.001]
  • [Cites] J Cell Biol. 2006 Feb 27;172(5):759-69 [16492808.001]
  • [Cites] Eur J Cell Biol. 2006 Apr;85(3-4):265-74 [16337026.001]
  • [Cites] J Neurosci. 2006 Mar 29;26(13):3390-5 [16571745.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Dec;32(6):605-14 [17083475.001]
  • [Cites] Mol Cell Neurosci. 2007 Feb;34(2):231-42 [17175165.001]
  • [Cites] J Cell Biol. 2007 Jun 18;177(6):1051-61 [17576798.001]
  • [Cites] J Cell Biol. 2007 Jun 18;177(6):1063-75 [17576799.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Jul;66(7):608-16 [17620986.001]
  • [Cites] Glia. 2008 Apr;56(5):506-15 [18240308.001]
  • [Cites] EMBO J. 1998 Aug 3;17(15):4328-39 [9687501.001]
  • (PMID = 19409384.001).
  • [ISSN] 1090-2430
  • [Journal-full-title] Experimental neurology
  • [ISO-abbreviation] Exp. Neurol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM054168-08; United States / NIGMS NIH HHS / GM / R01 GM054168; United States / NIGMS NIH HHS / GM / R01 GM054168-08
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Disulfides; 0 / Enzyme Inhibitors; 0 / IPA-3 compound; 0 / Naphthols; 452VLY9402 / Serine; EC 2.7.11.1 / p21-Activated Kinases; EC 3.6.5.2 / rac GTP-Binding Proteins
  • [Other-IDs] NLM/ NIHMS125967; NLM/ PMC2760977
  •  go-up   go-down


8. Müller S, Arnolds J, van Oosterhout A: Decision-making of vestibular schwannoma patients. Acta Neurochir (Wien); 2010 Jun;152(6):973-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decision-making of vestibular schwannoma patients.
  • BACKGROUND: Patients suffering from vestibular schwannoma can choose between four modalities of management:.
  • (1) wait-and-scan, (2) tumour resection, (3) radiosurgery and (4) fractionated radiotherapy.
  • METHOD: This study is based on postal questionnaire survey of 739 vestibular schwannoma patients (survey response rate, 78%).
  • The counselling should firstly be based on evidence-based medicine and secondly respond to the patients' individual life situation and preferences.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cooperative Behavior. Ethics, Medical. Evidence-Based Medicine / ethics. Female. Germany. Humans. Informed Consent / ethics. Interdisciplinary Communication. Male. Middle Aged. Patient Care Team / ethics. Patient Education as Topic / ethics. Postoperative Complications / etiology. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169371.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


9. Almeida LO, Custódio AC, Araújo JJ, Rey JA, Almeida JR, Santos MJ, Clara CA, Casartelli C: Mutational analysis of genes p14ARF, p15INK4b, p16INK4a, and PTEN in human nervous system tumors. Genet Mol Res; 2008;7(2):451-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer is one of the most common and severe problems in clinical medicine, and nervous system tumors represent about 2% of the types of cancer.
  • The cell cycle is a highly complex process, with a wide number of regulatory proteins involved, and such proteins can suffer alterations that transform normal cells into malignant ones.
  • The INK4 family members (CDK inhibitors) are the cell cycle regulators that block the progression of the cycle through the R point, causing an arrest in G1 stage.
  • The p14ARF (alternative reading frame) gene is a tumor suppressor that inhibits p53 degradation during the progression of the cell cycle.
  • The PTEN gene is related to the induction of growth suppression through cell cycle arrest, to apoptosis and to the inhibition of cell adhesion and migration.
  • The purpose of the present study was to assess the mutational state of the genes p14ARF, p15INK4b, p16INK4a, and PTEN in 64 human nervous system tumor samples.
  • Homozygous deletions were found in exon 2 of the p15INK4b gene and exon 3 of the p16INK4a gene in two schwannomas.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p15 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Nervous System Neoplasms / genetics. PTEN Phosphohydrolase / genetics. Tumor Suppressor Protein p14ARF / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18551412.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Protein p14ARF; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


10. Ammoun S, Cunliffe CH, Allen JC, Chiriboga L, Giancotti FG, Zagzag D, Hanemann CO, Karajannis MA: ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol; 2010 Aug;12(8):834-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.
  • Vestibular schwannomas (VS) arising sporadically or in patients with neurofibromatosis type 2 (NF2) consistently lack expression of Merlin, a tumor suppressor.
  • Recent evidence suggests that Merlin deficiency may result in abnormal activation of receptor tyrosine kinases (RTKs) and downstream signaling, promoting tumor growth.
  • Based on the findings, the small-molecule EGFR/ErbB2 kinase inhibitor lapatinib was selected for evaluation of target inhibition and treatment efficacy in our in vitro human schwannoma model.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Neuroma, Acoustic / metabolism. Quinazolines / pharmacology. Receptor, ErbB-2 / metabolism. Signal Transduction / drug effects
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Cell Survival / drug effects. Humans. Immunohistochemistry. Mitogen-Activated Protein Kinases / metabolism. Protein Array Analysis. Receptor, Epidermal Growth Factor / metabolism


11. Lee HK, Seo IA, Seo E, Seo SY, Lee HJ, Park HT: Netrin-1 induces proliferation of Schwann cells through Unc5b receptor. Biochem Biophys Res Commun; 2007 Nov 3;362(4):1057-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Netrin-1 induces proliferation of Schwann cells through Unc5b receptor.
  • However, accumulating evidence implies that they may also participate in the cell survival and apoptosis.
  • Here, we show that netrin-1 induces proliferation of Schwann cells.
  • Unc5b is the sole receptor expressed in RT4 schwannoma cells and adult primary Schwann cells, and netrin-1 and Unc5b are found to be expressed in the injured sciatic nerve.
  • It was also found that the netrin-1-induced Schwann cell proliferation was blocked by the specific inhibition of Unc5b expression with RNAi.
  • These data suggest that netrin-1 could be an endogenous trophic factor for Schwann cells in the injured peripheral nerves.
  • [MeSH-major] Nerve Growth Factors / administration & dosage. Receptors, Cell Surface / metabolism. Schwann Cells / metabolism. Sciatic Neuropathy / metabolism. Tumor Suppressor Proteins / administration & dosage
  • [MeSH-minor] Animals. Cell Line. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Male. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17825258.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nerve Growth Factors; 0 / Receptors, Cell Surface; 0 / Tumor Suppressor Proteins; 0 / Unc5b protein, rat; 158651-98-0 / netrin-1
  •  go-up   go-down


12. Kesser BW, Hashisaki GT, Holt JR: Gene transfer in human vestibular epithelia and the prospects for inner ear gene therapy. Laryngoscope; 2008 May;118(5):821-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A number of different viral vectors have been shown to transfect the varying cell types of the nonprimate mammalian inner ear.
  • Several routes of delivery have been identified for introduction of vectors into the inner ear while minimizing injury to existing structures and at the same time ensuring widespread distribution of the agent throughout the cochlea and the rest of the inner ear.
  • Human vestibular epithelia were harvested from patients undergoing labyrinthectomy, either for intractable Ménière's disease or vestibular schwannoma resection, and cultured for as long as 5 days.
  • In those experiments, recombinant, multiply-deleted, replication-deficient adenoviral vectors were used to transfect and express a reporter gene as well as the functionally relevant gene, wild-type KCNQ4, a potassium channel gene that when mutated causes the autosomal dominant HL DFNA2.Here, we review the current state of viral-mediated gene transfer in the inner ear and discuss different viral vectors, routes of delivery, and potential applications of gene therapy.

  • MedlinePlus Health Information. consumer health - Ear Disorders.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Otol. 1999 Jan;20(1):87-90 [9918180.001]
  • [Cites] Am J Otol. 1999 Jan;20(1):115-32 [9918184.001]
  • [Cites] Cell. 1999 Feb 5;96(3):437-46 [10025409.001]
  • [Cites] Hear Res. 1999 Feb;128(1-2):61-9 [10082284.001]
  • [Cites] J Neurophysiol. 1999 Apr;81(4):1881-8 [10200223.001]
  • [Cites] Neurosci Lett. 2005 Jun 3;380(3):234-8 [15862892.001]
  • [Cites] Mol Ther. 2005 Jun;11(6):843-8 [15922954.001]
  • [Cites] Mol Ther. 2005 Jun;11(6):849-55 [15922955.001]
  • [Cites] EMBO J. 2006 Feb 8;25(3):642-52 [16437162.001]
  • [Cites] Hear Res. 2006 Apr;214(1-2):37-44 [16580798.001]
  • [Cites] Otol Neurotol. 2007 Feb;28(2):223-31 [17255891.001]
  • [Cites] Gene Ther. 2007 Aug;14(15):1121-31 [17568767.001]
  • [Cites] J Neurosci. 2007 Aug 15;27(33):8940-51 [17699675.001]
  • [Cites] Gene Ther. 2000 Mar;7(5):377-83 [10694819.001]
  • [Cites] Hear Res. 2000 Apr;142(1-2):41-55 [10748327.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4333-8 [10760300.001]
  • [Cites] Nat Neurosci. 2000 Jun;3(6):580-6 [10816314.001]
  • [Cites] Rev Med Virol. 2000 May-Jun;10(3):185-202 [10815029.001]
  • [Cites] Ann N Y Acad Sci. 1999 Nov 28;884:270-91 [10842600.001]
  • [Cites] Gene Ther. 2000 Jun;7(12):1046-54 [10871754.001]
  • [Cites] Hear Res. 2000 Aug;146(1-2):28-34 [10913881.001]
  • [Cites] Hear Res. 2000 Aug;146(1-2):134-42 [10913890.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):51-5 [10973247.001]
  • [Cites] Nat Genet. 2001 Jan;27(1):99-102 [11138007.001]
  • [Cites] Nat Genet. 2001 Jan;27(1):103-7 [11138008.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2000 Nov;257(9):469-72 [11131371.001]
  • [Cites] Am J Hum Genet. 2001 Jan;68(1):26-37 [11090341.001]
  • [Cites] Hear Res. 2001 Jan;151(1-2):106-114 [11124456.001]
  • [Cites] Hear Res. 2001 Jan;151(1-2):30-40 [11124449.001]
  • [Cites] Hum Gene Ther. 2001 Mar 20;12(5):539-48 [11268286.001]
  • [Cites] Hum Gene Ther. 2001 May 1;12(7):773-81 [11339894.001]
  • [Cites] Hum Gene Ther. 1999 Mar 20;10(5):769-74 [10210144.001]
  • [Cites] Am J Otol. 1999 May;20(3):317-24 [10337971.001]
  • [Cites] Science. 1999 Jun 11;284(5421):1837-41 [10364557.001]
  • [Cites] Hear Res. 2002 Nov;173(1-2):187-97 [12372646.001]
  • [Cites] J Comp Neurol. 2002 Dec 16;454(3):350-60 [12442325.001]
  • [Cites] Neurosci Lett. 2002 Dec 19;335(1):13-6 [12457731.001]
  • [Cites] Audiol Neurootol. 2002 Nov-Dec;7(6):324-34 [12463195.001]
  • [Cites] Adv Exp Med Biol. 2002;513:41-86 [12575817.001]
  • [Cites] Hum Mol Genet. 2003 Mar 1;12(5):463-71 [12588794.001]
  • [Cites] Am J Hum Genet. 2003 May;72(5):1315-22 [12687499.001]
  • [Cites] Mol Ther. 2003 Apr;7(4):484-92 [12727111.001]
  • [Cites] J Neurosci. 2003 Jun 1;23(11):4395-400 [12805278.001]
  • [Cites] Mol Cell Neurosci. 2003 Jun;23(2):169-79 [12812751.001]
  • [Cites] Hear Res. 2003 Jul;181(1-2):100-8 [12855368.001]
  • [Cites] Ear Hear. 2003 Aug;24(4):342-8 [12923425.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Jul-Aug;65(4):211-4 [14564095.001]
  • [Cites] Hum Mol Genet. 2003 Dec 15;12(24):3215-23 [14570705.001]
  • [Cites] Mol Ther. 2004 Feb;9(2):173-81 [14759801.001]
  • [Cites] Hear Res. 2004 Apr;190(1-2):25-30 [15051127.001]
  • [Cites] Audiol Neurootol. 2004 May-Jun;9(3):135-43 [15084818.001]
  • [Cites] Methods. 2004 Jun;33(2):173-8 [15121172.001]
  • [Cites] Acta Otolaryngol Suppl. 2004 Aug;(553):19-22 [15277030.001]
  • [Cites] Otolaryngol Clin North Am. 2004 Oct;37(5):1091-108 [15474113.001]
  • [Cites] Biochim Biophys Acta. 1990 Mar 30;1023(1):124-32 [2317491.001]
  • [Cites] Nat Genet. 1994 Oct;8(2):148-54 [7842013.001]
  • [Cites] Nature. 1995 Mar 2;374(6517):60-1 [7870171.001]
  • [Cites] Neuron. 1995 Jun;14(6):1153-64 [7605630.001]
  • [Cites] Annu Rev Microbiol. 1995;49:807-38 [8561480.001]
  • [Cites] Neurosci Lett. 1996 Mar 29;207(2):137-41 [8731440.001]
  • [Cites] J Mol Med (Berl). 1996 Apr;74(4):171-82 [8740648.001]
  • [Cites] Neuroreport. 1996 Mar 22;7(4):889-94 [8724667.001]
  • [Cites] Hum Gene Ther. 1996 Jan 20;7(2):173-82 [8788168.001]
  • [Cites] Hum Gene Ther. 1999 Jul 20;10(11):1867-73 [10446926.001]
  • [Cites] Hear Res. 1999 Aug;134(1-2):1-8 [10452370.001]
  • [Cites] Hear Res. 1999 Oct;136(1-2):124-30 [10511631.001]
  • [Cites] Audiol Neurootol. 1999 Nov-Dec;4(6):271-85 [10516388.001]
  • [Cites] Nature. 2004 Dec 9;432(7018):723-30 [15483558.001]
  • [Cites] Nat Med. 2005 Mar;11(3):271-6 [15711559.001]
  • [Cites] J Assoc Res Otolaryngol. 2000 Dec;1(4):315-25 [11547811.001]
  • [Cites] Mol Ther. 2001 Dec;4(6):575-85 [11735342.001]
  • [Cites] Acta Otolaryngol. 2001 Jan;121(2):157-63 [11349769.001]
  • [Cites] Gene Ther. 2001 May;8(10):789-94 [11420643.001]
  • [Cites] Am J Hum Genet. 2001 Sep;69(3):635-40 [11468689.001]
  • [Cites] Curr Top Microbiol Immunol. 2002;261:31-52 [11892252.001]
  • [Cites] Audiol Neurootol. 2002 May-Jun;7(3):157-60 [12053137.001]
  • [Cites] Laryngoscope. 2002 Aug;112(8 Pt 1):1325-34 [12172239.001]
  • [Cites] Gene Ther. 1996 Jul;3(7):588-92 [8818645.001]
  • [Cites] Neurosci Lett. 1996 Feb 16;205(1):17-20 [8867010.001]
  • [Cites] Nat Genet. 1997 Feb;15(2):186-9 [9020846.001]
  • [Cites] Int J Dev Neurosci. 1997 Jul;15(4-5):577-83 [9263034.001]
  • [Cites] Int J Dev Neurosci. 1997 Jul;15(4-5):595-600 [9263036.001]
  • [Cites] Nat Genet. 1997 Nov;17(3):267-8 [9354783.001]
  • [Cites] Hear Res. 1997 Dec;114(1-2):139-47 [9447928.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2509-14 [9482916.001]
  • [Cites] Development. 1998 Feb;125(4):557-66 [9435277.001]
  • [Cites] Gene Ther. 1998 Feb;5(2):277-81 [9578849.001]
  • [Cites] Am J Otol. 1998 May;19(3):390-5 [9596192.001]
  • [Cites] Science. 1998 May 29;280(5368):1444-7 [9603735.001]
  • [Cites] Science. 1998 May 29;280(5368):1447-51 [9603736.001]
  • [Cites] Otolaryngol Head Neck Surg. 1998 Jul;119(1):7-13 [9674508.001]
  • [Cites] Neuroreport. 1998 Jul 13;9(10):2183-7 [9694197.001]
  • [Cites] J Neurosci. 1998 Oct 1;18(19):7811-21 [9742150.001]
  • [Cites] Hear Res. 1998 Oct;124(1-2):17-26 [9822899.001]
  • [Cites] Brain Res. 1999 Jan 9;815(2):317-25 [9878807.001]
  • (PMID = 18300702.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / DC005439-05; United States / NIDCD NIH HHS / DC / R01 DC005439; United States / NIDCD NIH HHS / DC / R56 DC005439; United States / NIDCD NIH HHS / DC / R01 DC005439-05
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Brain-Derived Neurotrophic Factor; 0 / Glial Cell Line-Derived Neurotrophic Factor; 0 / KCNQ Potassium Channels; 0 / KCNQ4 protein, human
  • [Other-IDs] NLM/ NIHMS86203; NLM/ PMC2642479
  •  go-up   go-down


13. Vellin JF, Bozorg Grayeli A, Kalamarides M, Fond C, Bouccara D, Sterkers O: Intratumoral and brainstem hemorrhage in a patient with vestibular schwannoma and oral anticoagulant therapy. Otol Neurotol; 2006 Feb;27(2):209-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral and brainstem hemorrhage in a patient with vestibular schwannoma and oral anticoagulant therapy.
  • OBJECTIVE: To report the first case of spontaneous intratumoral and brainstem hemorrhage in a patient with a vestibular schwannoma.
  • PATIENT: A 73-year-old woman with a vestibular schwannoma, anti-vitamin K overdose, and arterial hypertension experienced a rapid onset of headache, facial palsy, diplopia, and hoarseness.
  • CONCLUSION: Intratumoral, subarachnoid, and brainstem hemorrhages can occur in patients with vestibular schwannoma.
  • Oral anticoagulant therapy is a risk factor for tumor-related hemorrhage.
  • [MeSH-minor] Administration, Oral. Aged. Diplopia. Drug Overdose. Facial Paralysis. Fatal Outcome. Female. Headache. Hoarseness. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16436991.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants
  • [Number-of-references] 14
  •  go-up   go-down


14. De Valck CF, Vereeck L, Wuyts FL, Van de Heyning PH: Failure of gamma-aminobutyrate acid-beta agonist baclofen to improve balance, gait, and postural control after vestibular schwannoma resection. Otol Neurotol; 2009 Apr;30(3):350-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Failure of gamma-aminobutyrate acid-beta agonist baclofen to improve balance, gait, and postural control after vestibular schwannoma resection.
  • INTRODUCTION: Incomplete postural control often occurs after vestibular schwannoma (VS) surgery.
  • METHODS: Thirteen patients who underwent VS resection were included and compared with a matched group of patients.
  • [MeSH-major] Baclofen / pharmacology. GABA Agonists / pharmacology. GABA-B Receptor Agonists. Gait / drug effects. Neuroma, Acoustic / surgery. Postural Balance / drug effects. Posture / physiology. Vestibular Diseases / surgery
  • [MeSH-minor] Adult. Dizziness / drug therapy. Dizziness / psychology. Female. Humans. Male. Middle Aged. Surveys and Questionnaires. Treatment Outcome

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Guide to Good Posture.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19174711.001).
  • [ISSN] 1537-4505
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GABA Agonists; 0 / GABA-B Receptor Agonists; H789N3FKE8 / Baclofen
  •  go-up   go-down


15. Ferraresi V, Ciccarese M, Cercato MC, Nuzzo C, Zeuli M, Di Filippo F, Giannarelli D, Cognetti F: Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study. Cancer Chemother Pharmacol; 2008 Dec;63(1):149-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Fourteen patients with advanced locally unresectable and/or metastatic, pretreated STSs (seven leiomyosarcoma, three malignant schwannoma, one synovialsarcoma, one malignant fibrous histiocytoma, one endometrial stromal cell sarcoma, one undifferentiated) were treated with gemcitabine 10 mg/m(2)/min/week over 100 min given for 3 weeks out of 4.
  • The median age was 52 years (range 27-77), male/female ratio was 3/11, and the median WHO performance status was 0 (range 0-1).
  • The median number of previous medical treatments for advanced disease was 1 (range 1-2).
  • Three patients (two leiomyosarcoma and one schwannoma) (21%) obtained a stabilization of disease.
  • Nevertheless, an interesting tumor growth control rate was observed in specific histological variants (i.e., leiomyosarcoma), thus confirming data from recent controlled clinical trials.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease Progression. Dose-Response Relationship, Drug. Female. Gastrointestinal Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18351342.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


16. Ishii K, Zaitsu M, Yonemitsu N, Kan Y, Hamasaki Y, Matsuo M: 5-lipoxygenase pathway promotes cell proliferation in human glioma cell lines. Clin Neuropathol; 2009 Nov-Dec;28(6):445-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-lipoxygenase pathway promotes cell proliferation in human glioma cell lines.
  • METHODS: We immunohistochemically evaluated the profile of 5-LO expression in various types of brain tumors obtained from 42 patients, and examined the proliferative effects of the 5-LO pathway in human glioma cell lines using a proliferation assay.
  • RESULTS: Immunohistochemistry of glioblastomas, astrocytomas, meningiomas, medulloblastomas, craniopharyngiomas, ependymomas, neurinomas, oligodendrogliomas, malignant lymphomas, dysembryoplastic neuroepithelial and metastatic brain tumors revealed 5-LO expression in the cytoplasm and nuclei or nuclear envelopes of tumor cells.
  • The 5-LO inhibitor A861 and the LTA4 hydrolase inhibitor Bestatin dose-dependently suppressed the proliferation of A172 cells, a glioma cell line.
  • CONCLUSIONS: We confirmed the expression of 5-LO in various human brain tumors and demonstrated the partial suppression of tumor growth by inhibitors of the 5-LO-LTA4 hydrolase pathway in human glioma cell lines.
  • [MeSH-major] Arachidonate 5-Lipoxygenase / physiology. Brain Neoplasms / pathology. Cell Proliferation. Glioma / pathology. Signal Transduction / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / pathology. Astrocytoma / physiopathology. Child. Child, Preschool. Dose-Response Relationship, Drug. Female. Glioblastoma / pathology. Glioblastoma / physiopathology. Humans. Leucine / analogs & derivatives. Leucine / pharmacology. Leukotriene A4 / antagonists & inhibitors. Leukotriene A4 / physiology. Lipoxygenase Inhibitors. Male. Meningioma / pathology. Meningioma / physiopathology. Middle Aged. Protease Inhibitors / pharmacology. Tumor Cells, Cultured. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. L-Leucine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19919819.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Leukotriene A4; 0 / Lipoxygenase Inhibitors; 0 / Protease Inhibitors; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; GMW67QNF9C / Leucine; I0J33N5627 / ubenimex
  •  go-up   go-down


17. Clark JJ, Provenzano M, Diggelmann HR, Xu N, Hansen SS, Hansen MR: The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. Otol Neurotol; 2008 Sep;29(6):846-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.
  • OBJECTIVE: To analyze the ability of ErbB inhibitors to reduce the growth of vestibular schwannoma (VS) xenografts.
  • METHODS: Vestibular schwannoma xenografts were established in the interscapular fat pad in nude mice for 4 weeks.
  • Initially, a small cohort of animals was treated with the ErbB2 inhibitor trastuzumab or saline for 2 weeks.
  • Animals also received bromodeoxyuridine injections to label proliferating cells.
  • In a longer-term experiment, animals were randomized to receive trastuzumab, erlotinib (an ErbB kinase inhibitor), or placebo for 12 weeks.
  • Tumor growth was monitored by magnetic resonance imaging during the treatment period.
  • Cell death was analyzed by terminal deoxynucleotidyl transferase-mediated dUTP-biotin end labeling of fragmented DNA.
  • CONCLUSION: In this preliminary study, the ErbB inhibitors trastuzumab and erlotinib decreased growth of VS xenografts in nude mice, raising the possibility of using ErbB inhibitors in the management of patients with schwannomas, particularly those with neurofibromatosis Type 2.

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • [Cites] Otol Neurotol. 2004 Mar;25(2):155-9 [15021776.001]
  • [Cites] Arch Neurol. 1994 Feb;51(2):201-7 [8304846.001]
  • [Cites] Acta Otolaryngol. 1994 Jul;114(4):399-405 [7526595.001]
  • [Cites] Hum Genet. 1996 Aug;98(2):203-6 [8698343.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1649-54 [9403715.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21-6 [15142631.001]
  • [Cites] Otol Neurotol. 2004 Sep;25(5):811-7 [15354016.001]
  • [Cites] Neurosurgery. 1990 Apr;26(4):598-605 [2330081.001]
  • [Cites] J Neurooncol. 1992 Oct;14(2):101-12 [1432035.001]
  • [Cites] Genes Dev. 1998 Apr 15;12(8):1121-33 [9553042.001]
  • [Cites] Hum Mol Genet. 1998 Dec;7(13):2095-101 [9817927.001]
  • [Cites] J Neurosurg. 1999 Apr;90(4):617-23 [10193604.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18200-5 [15598747.001]
  • [Cites] Laryngoscope. 2005 Mar;115(3):450-4 [15744156.001]
  • [Cites] Otolaryngol Clin North Am. 2005 Aug;38(4):653-70 [16005724.001]
  • [Cites] Oncogene. 2005 Aug 25;24(36):5589-605 [15897877.001]
  • [Cites] Breast Cancer Res Treat. 2005 Aug;92(3):251-63 [16155796.001]
  • [Cites] Mol Cells. 2005 Oct 31;20(2):196-200 [16267393.001]
  • [Cites] Hum Gene Ther. 2006 Jan;17(1):20-30 [16409122.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Feb 24;340(4):1151-7 [16405865.001]
  • [Cites] Otol Neurotol. 2006 Feb;27(2):197-208 [16436990.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Feb;65(2):162-75 [16462207.001]
  • [Cites] Glia. 2006 Apr 15;53(6):593-600 [16432850.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4463-8 [16537381.001]
  • [Cites] J Med Genet. 2006 Apr;43(4):289-94 [16155191.001]
  • [Cites] Otol Neurotol. 2006 Apr;27(3):380-92 [16639278.001]
  • [Cites] Otol Neurotol. 2006 Aug;27(5):705-12 [16868519.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4925-32 [16914581.001]
  • [Cites] Laryngoscope. 2006 Nov;116(11):2018-26 [17075413.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3505-12 [17094474.001]
  • [Cites] J Neurol. 2006 Dec;253(12):1533-41 [17219030.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):520-7 [17234759.001]
  • [Cites] Mol Ther. 2007 Feb;15(2):279-86 [17235305.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1228-38 [17283159.001]
  • [Cites] Otol Neurotol. 2007 Aug;28(5):708-14 [17667776.001]
  • [Cites] Br J Cancer. 2007 Aug 20;97(4):453-7 [17667926.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2007 Oct;15(5):341-6 [17823551.001]
  • [Cites] J Clin Neurosci. 2007 Dec;14(12):1199-206 [17964790.001]
  • [Cites] Laryngoscope. 2008 Jan;118(1):87-93 [18090258.001]
  • [Cites] Otol Neurotol. 2008 Jan;29(1):50-7 [18199957.001]
  • [Cites] Otol Neurotol. 2008 Jan;29(1):79-85 [18199961.001]
  • [Cites] Glia. 2000 Jan 15;29(2):104-11 [10625327.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] Hum Mol Genet. 2001 Feb 1;10(3):271-82 [11159946.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):279-90 [12082543.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):354-62 [12118253.001]
  • [Cites] Br J Neurosurg. 2002 Jun;16(3):284-9 [12201399.001]
  • [Cites] Neoplasia. 2002 Nov-Dec;4(6):501-9 [12407444.001]
  • [Cites] Curr Opin Neurol. 2003 Feb;16(1):27-33 [12544854.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Mar 7;302(2):238-45 [12604337.001]
  • [Cites] Hum Mol Genet. 2003 Jun 1;12(11):1211-21 [12761036.001]
  • [Cites] Glia. 2003 Aug;43(2):104-18 [12838503.001]
  • [Cites] J Neurosci. 2003 Aug 13;23(19):7269-80 [12917360.001]
  • [Cites] J Neurosurg. 2003 Sep;99(3):480-3 [12959433.001]
  • [Cites] Int J Oncol. 2003 Dec;23(6):1493-500 [14612918.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):109-10 [14693854.001]
  • [Cites] Cancer J. 2004 Jan-Feb;10(1):20-6 [15000491.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • (PMID = 18636037.001).
  • [ISSN] 1537-4505
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / K08 DC006211; United States / NIDCD NIH HHS / DC / K08 DC006211-01A1; United States / NIDCD NIH HHS / DC / KO8 DC006211
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; P188ANX8CK / Trastuzumab
  • [Other-IDs] NLM/ NIHMS85822; NLM/ PMC2652856
  •  go-up   go-down


18. Niemczyk K, Czernicki Z, Podogrodzki P, Andrychowski J, Bruzgielewicz A: [Extended translabyrinthine approach in treatment of vestibular schwannomas]. Otolaryngol Pol; 2001;55(1):23-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extended translabyrinthine approach in treatment of vestibular schwannomas].
  • [Transliterated title] Poszerzona droga przezbłednikowa w leczeniu guzów nerwu przedsionkowo-ślimakowego.
  • Results of removal of vestibular schwannomas using translabyrintine approach were presented.
  • Authors underline, that the translabyrintine approach permits to obtain enough wide insight to ponto-cerebellar angle to remove safely, both little and large, vestibular schwannomas.

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11355472.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


19. Yi C, Wilker EW, Yaffe MB, Stemmer-Rachamimov A, Kissil JL: Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2. Cancer Res; 2008 Oct 1;68(19):7932-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2.
  • Neurofibromatosis type 2 (NF2) is a dominantly inherited cancer disorder caused by mutations at the NF2 gene locus.
  • Merlin, the protein product of the NF2 gene, has been shown to negatively regulate Rac1 signaling by inhibiting its downstream effector kinases, the p21-activated kinases (Pak).
  • Given the implication of Paks in tumorigenesis, it is plausible that merlin's tumor suppressive function might be mediated, at least in part, via inhibition of the Paks.
  • First, analysis of primary schwannoma samples derived from NF2 patients showed that in a significant fraction of the tumors, the activity of Pak1 was highly elevated.
  • Finally, while attempting to silence Pak1 in rat schwannoma cells, we found that these cells were unable to tolerate long-term Pak1 inhibition and rapidly moved to restore Pak1 levels by shutting down Pak1 shRNA expression through a methylation-dependent mechanism.
  • In addition, the finding that the shRNA-mediated Pak1 suppression was silenced rapidly by methylation raises questions about the future application of such technologies for the treatment of diseases such as cancer.

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2000 Sep;2(9):593-600 [10980699.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):520-7 [17234759.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):17347-53 [11278486.001]
  • [Cites] Mol Cell Biol. 2001 Aug;21(15):5179-89 [11438672.001]
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):883-6 [11719502.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10394-9 [11782491.001]
  • [Cites] Oncogene. 2002 Sep 5;21(39):5990-7 [12203111.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):401-6 [12590264.001]
  • [Cites] Hum Mol Genet. 2003 Jun 1;12(11):1211-21 [12761036.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):841-9 [14580336.001]
  • [Cites] Cancer J. 2004 Jan-Feb;10(1):20-6 [15000491.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18559-66 [14981079.001]
  • [Cites] Mol Cell Biol. 1997 Aug;17(8):4454-64 [9234703.001]
  • [Cites] Mol Cell Biol. 2005 Mar;25(6):2384-94 [15743831.001]
  • [Cites] Adv Genet. 2005;54:117-42 [16096010.001]
  • [Cites] J Neurosci. 2006 Mar 29;26(13):3390-5 [16571745.001]
  • [Cites] Semin Pediatr Neurol. 2006 Mar;13(1):21-6 [16818172.001]
  • [Cites] Nature. 2006 Aug 3;442(7102):576-9 [16885985.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):36238-44 [10945974.001]
  • (PMID = 18829550.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA124495; United States / NCI NIH HHS / CA / F32 CA123752-01; United States / NCI NIH HHS / CA / F32 CA123752-03; United States / NINDS NIH HHS / NS / NS024279-19; United States / NCI NIH HHS / CA / CA101502-02; United States / NINDS NIH HHS / NS / P01 NS024279-19; United States / NCI NIH HHS / CA / CA123752-01; United States / NCI NIH HHS / CA / CA123752-02; United States / NCI NIH HHS / CA / F32 CA101502-02; United States / NCI NIH HHS / CA / CA123752-03; United States / NCI NIH HHS / CA / F32 CA101502; United States / NINDS NIH HHS / NS / P01 NS024279; United States / NCI NIH HHS / CA / F32 CA123752-02; United States / NCI NIH HHS / CA / F32 CA123752
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; EC 2.7.11.1 / p21-Activated Kinases
  • [Other-IDs] NLM/ NIHMS112457; NLM/ PMC2707059
  •  go-up   go-down


20. James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, Gusella JF, Ramesh V: NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol; 2009 Aug;29(15):4250-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
  • Inactivating mutations of the neurofibromatosis 2 (NF2) gene, NF2, result predominantly in benign neurological tumors, schwannomas and meningiomas, in humans; however, mutations in murine Nf2 lead to a broad spectrum of cancerous tumors.
  • The tumor-suppressive function of the NF2 protein, merlin, a membrane-cytoskeleton linker, remains unclear.
  • Here, we identify the mammalian target of rapamycin complex 1 (mTORC1) as a novel mediator of merlin's tumor suppressor activity.
  • Merlin-deficient human meningioma cells and merlin knockdown arachnoidal cells, the nonneoplastic cell counterparts of meningiomas, exhibit rapamycin-sensitive constitutive mTORC1 activation and increased growth.
  • Conversely, the exogenous expression of wild-type merlin isoforms, but not a patient-derived L64P mutant, suppresses mTORC1 signaling.

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Schwannoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2004 Nov 18;23(54):8815-25 [15467741.001]
  • [Cites] J Virol Methods. 2004 Dec 15;122(2):131-9 [15542136.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Cell. 2005 Apr 22;121(2):179-93 [15851026.001]
  • [Cites] Genes Dev. 2005 Oct 1;19(19):2265-77 [16204178.001]
  • [Cites] J Cell Biol. 2005 Oct 24;171(2):361-71 [16247032.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95 [16331155.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):27-36 [16341207.001]
  • [Cites] Cell. 2006 Feb 10;124(3):471-84 [16469695.001]
  • [Cites] Ann Neurol. 2006 Mar;59(3):490-8 [16453317.001]
  • [Cites] Mol Cell. 2006 Apr 21;22(2):159-68 [16603397.001]
  • [Cites] J Cell Biol. 2006 Apr 24;173(2):279-89 [16636147.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):729-34 [16915295.001]
  • [Cites] Mol Cell. 2006 Oct 20;24(2):185-97 [17052453.001]
  • [Cites] Nat Cell Biol. 2007 Mar;9(3):316-23 [17277771.001]
  • [Cites] Mol Cell. 2007 Mar 23;25(6):903-15 [17386266.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):9-22 [17613433.001]
  • [Cites] Cell Res. 2007 Aug;17(8):666-81 [17680028.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2747-61 [17974916.001]
  • [Cites] N Engl J Med. 2008 Jan 10;358(2):140-51 [18184959.001]
  • [Cites] Neurobiol Dis. 2008 Feb;29(2):278-92 [17962031.001]
  • [Cites] Oncogene. 2008 Feb 14;27(8):1106-13 [17724476.001]
  • [Cites] Biochem J. 2008 Jun 1;412(2):179-90 [18466115.001]
  • [Cites] Mol Cell Biol. 2008 Jun;28(12):4104-15 [18411301.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):812-6 [14871804.001]
  • [Cites] J Biol Chem. 2002 Nov 15;277(46):44180-6 [12226091.001]
  • [Cites] Ann Hum Genet. 2003 Jan;67(Pt 1):87-96 [12556239.001]
  • [Cites] Genes Dev. 2003 May 1;17(9):1090-100 [12695331.001]
  • [Cites] Nat Cell Biol. 2000 May;2(5):281-7 [10806479.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):293-300 [11213968.001]
  • [Cites] Genes Dev. 2001 Apr 15;15(8):968-80 [11316791.001]
  • [Cites] Annu Rev Biochem. 2001;70:535-602 [11395417.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Aug;3(8):586-99 [12154370.001]
  • [Cites] J Clin Invest. 2003 Oct;112(8):1223-33 [14561707.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):580-7 [14724586.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13489-94 [15342917.001]
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Curr Opin Genet Dev. 1996 Feb;6(1):87-92 [8791482.001]
  • [Cites] EMBO J. 1996 Oct 1;15(19):5256-67 [8895571.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4141-7 [9307305.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2505-9 [9395247.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14723-8 [9843956.001]
  • [Cites] Nat Cell Biol. 2004 Nov;6(11):1122-8 [15467718.001]
  • [Cites] J Cell Biol. 2004 Nov 8;167(3):399-403 [15533996.001]
  • [Cites] J Cell Biol. 2004 Dec 20;167(6):1171-82 [15611338.001]
  • (PMID = 19451225.001).
  • [ISSN] 1098-5549
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P30 NS045776; United States / NINDS NIH HHS / NS / NS 045776; United States / NIMH NIH HHS / MH / R21 MH079213; United States / NIMH NIH HHS / MH / MH 079213; United States / NINDS NIH HHS / NS / P01 NS024279; United States / NCI NIH HHS / CA / R01 CA122617-04; United States / NINDS NIH HHS / NS / NS 024279; United States / NCI NIH HHS / CA / CA122617-04; United States / NCI NIH HHS / CA / R01 CA122617
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Multiprotein Complexes; 0 / Neurofibromin 2; 0 / Proteins; 0 / RNA, Small Interfering; 0 / Transcription Factors; 0 / mechanistic target of rapamycin complex 1; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC2715803
  •  go-up   go-down


21. Jannatipour M, Dion P, Khan S, Jindal H, Fan X, Laganière J, Chishti AH, Rouleau GA: Schwannomin isoform-1 interacts with syntenin via PDZ domains. J Biol Chem; 2001 Aug 31;276(35):33093-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The neurofibromatosis type 2 gene (NF2) is involved in the pathogenesis of benign tumors of the human nervous system.
  • The NF2 protein, called schwannomin or merlin, is inactivated in virtually all schwannomas and meningiomas.
  • The molecular mechanisms by which schwannomin functions as a tumor suppressor is unknown but believed to involve plasma membrane-cytoskeletal interactions.
  • The C terminus 25 amino acids of sch-1 and the two PDZ domains of syntenin mediate their binding, and mutations introduced within the VAFFEEL region of sch-1 defined a sequence crucial for syntenin recognition.
  • We have showed that the two proteins interacted in vitro and in vivo and localized underneath the plasma membrane.
  • [MeSH-major] Carrier Proteins / chemistry. Carrier Proteins / metabolism. Intracellular Signaling Peptides and Proteins. Membrane Proteins / chemistry. Membrane Proteins / metabolism
  • [MeSH-minor] 3T3 Cells. Alternative Splicing. Amino Acid Sequence. Amino Acid Substitution. Animals. Binding Sites. Cell Membrane / metabolism. Cloning, Molecular. Cytoskeleton. Doxycycline / pharmacology. Gene Expression Regulation / drug effects. Gene Library. Genes, Neurofibromatosis 2. Glutathione Transferase / metabolism. HeLa Cells. Humans. Mice. Molecular Sequence Data. Mutagenesis, Site-Directed. Neurofibromin 2. Protein Isoforms / chemistry. Protein Isoforms / genetics. Protein Isoforms / metabolism. Recombinant Fusion Proteins / chemistry. Recombinant Fusion Proteins / metabolism. Recombinant Proteins / chemistry. Recombinant Proteins / metabolism. Saccharomyces cerevisiae. Syntenins. Transfection

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11432873.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA66263; United States / NHLBI NIH HHS / HL / HL60755
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Neurofibromin 2; 0 / Protein Isoforms; 0 / Recombinant Fusion Proteins; 0 / Recombinant Proteins; 0 / SDCBP protein, human; 0 / Syntenins; EC 2.5.1.18 / Glutathione Transferase; N12000U13O / Doxycycline
  •  go-up   go-down


22. Ozgen B, Oguz B, Dolgun A: Diagnostic accuracy of the constructive interference in steady state sequence alone for follow-up imaging of vestibular schwannomas. AJNR Am J Neuroradiol; 2009 May;30(5):985-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic accuracy of the constructive interference in steady state sequence alone for follow-up imaging of vestibular schwannomas.
  • BACKGROUND AND PURPOSE: Vestibular schwannoma (VS) is a benign, slow-growing tumor, and radiologic monitoring is an acceptable alternative to surgery in small lesions and in elderly patients.
  • However, gadolinium-based contrast agents have side effects and should be used only when definitely indicated.
  • The purpose of this study was to evaluate the diagnostic accuracy of the constructive interference in steady state (CISS) sequence used without postcontrast sequences for the follow-up imaging of vs. MATERIALS AND METHODS: MR imaging examinations of 18 patients were retrospectively evaluated by 2 radiologists.
  • CONCLUSIONS: Noncontrast CISS-only technique may be a viable alternative to routine contrast-enhanced sequences for the follow-up of overall lesion size in patients with VS; however, treatment-related changes internal to the tumor are less noticeable using the CISS sequence.

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19193761.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Magliulo G, D'Amico R, Di Cello P: Delayed facial palsy after vestibular schwannoma resection: clinical data and prognosis. J Otolaryngol; 2003 Dec;32(6):400-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed facial palsy after vestibular schwannoma resection: clinical data and prognosis.
  • PURPOSE: The object of the present study was to review a series of surgically removed vestibular schwannoma tumours to establish the incidence of delayed facial palsy and to evaluate the course of recovery according to the possible etiology (surgical postoperative edema or viral reactivation) with reference to the time of onset.
  • MATERIALS AND METHODS: The study group was composed of 98 patients with vestibular schwannoma.
  • Sex, age, location, and extent of tumour and postoperative complications were all taken into consideration in the final evaluation.
  • The course of each patient's postoperative facial function was graded according to House and Brackmann's six-grade scale.
  • The incidence rate of the delayed facial dysfunction was not influenced by age, sex, or the size of the tumour.
  • The prognosis of the facial dysfunction was favourable in the majority of cases, and, in fact, there were only five grade III to IV cases 1 year later.
  • Facial dysfunction was over grade III in the majority of the latter five cases, and the period of recovery was long.
  • CONCLUSIONS: Eighty percent of our patients with delayed facial palsy following vestibular schwannoma resection were classified as having excellent or good function.
  • In the remaining patients who had a less favourable recovery, the palsy was more severe, and the onset occurred after some time.
  • This seems to agree with those who are of the opinion that the complication is due to viral reactivation.
  • In these patients, it is advisable to start aggressive medical therapy with antiviral agents such as acyclovir as soon as possible.
  • [MeSH-minor] Acyclovir / therapeutic use. Adult. Aged. Antiviral Agents / therapeutic use. Edema / complications. Edema / etiology. Facial Nerve / physiopathology. Female. Humans. Incidence. Male. Middle Aged. Neurosurgical Procedures / adverse effects. Neurosurgical Procedures / methods. Prognosis. Recovery of Function. Retrospective Studies. Steroids / therapeutic use. Time Factors. Treatment Outcome. Virus Activation / drug effects

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • Hazardous Substances Data Bank. ACYCLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14967087.001).
  • [ISSN] 0381-6605
  • [Journal-full-title] The Journal of otolaryngology
  • [ISO-abbreviation] J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Steroids; X4HES1O11F / Acyclovir
  •  go-up   go-down


24. Karelin AA, Demidova VS, Globa AG, Devlikanova ASh, Panova NV, Tsvirkun VV, Budaev KD, Buriev IM, Vishnevskiĭ AA: [Effects of some growth factors and cytokines on ATP synthesis by plasma-membrane-enriched particles isolated from different human tumors]. Vestn Ross Akad Med Nauk; 2000;(3):21-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Polypeptide growth factors, such as EGF, FGF, NGF, TNF, insulin, and the cytokine IL-2, were studied on the accumulation of adenosine-5'-triphosphate (ATP) by the preparations of plasma-membrane-enriched particles isolated from the target tissues of human malignant tumors.
  • The tumor (transformed) cell plasma membranes of the lung, bowel, stomach, pancreas, as well as the cells of neurinoma and a retroperitoneal extra-organ malignant tumor (leiomyosarcoma) are demonstrated to be able to synthesize ATP from inorganic phosphate and ADP under aerobic conditions human with the participation of the cyanide-insensitive proton phoric NADH-bound transversely oriented chain.

  • Hazardous Substances Data Bank. QUERCETIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10765731.001).
  • [ISSN] 0869-6047
  • [Journal-full-title] Vestnik Rossiiskoi akademii meditsinskikh nauk
  • [ISO-abbreviation] Vestn. Akad. Med. Nauk SSSR
  • [Language] RUS
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Growth Substances; 0 / Interleukin-2; 0 / Tyrphostins; 118409-58-8 / tyrphostin 25; 61D2G4IYVH / Adenosine Diphosphate; 8L70Q75FXE / Adenosine Triphosphate; 9IKM0I5T1E / Quercetin; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


25. Møller AR: Tinnitus: presence and future. Prog Brain Res; 2007;166:3-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subjective tinnitus often occurs in connection with hearing loss such as may occur after exposure to loud sounds (noise), or after administration of drugs such as certain antibiotics, but often no cause can be found.
  • Tinnitus is a part of the symptoms of Ménière's disease and individuals with vestibular Schwannoma almost always have tinnitus.
  • Some individuals who have severe tinnitus hear sounds as distorted and some have hyperacusis (reduced tolerance to sounds) or phonophobia (fear of sounds).
  • The anatomical location of the physiological abnormality of chronic subjective tinnitus, however, is rarely in the ear but more often in the auditory nervous system.
  • Since there are many kinds of subjective tinnitus, search for a (single) cure for tinnitus is futile.
  • [MeSH-minor] Animals. Humans. Prevalence. Risk Factors

  • Genetic Alliance. consumer health - Tinnitus.
  • MedlinePlus Health Information. consumer health - Tinnitus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17956767.001).
  • [ISSN] 0079-6123
  • [Journal-full-title] Progress in brain research
  • [ISO-abbreviation] Prog. Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 90
  •  go-up   go-down


26. Koppelstaetter F, Siedentopf CM, Rhomberg P, Lechner-Steinleitner S, Mottaghy FM, Eisner W, Golaszewski SM: [Functional magnetic resonance imaging before motor cortex stimulation for phantom limb pain]. Nervenarzt; 2007 Dec;78(12):1435-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study deals with the diagnostic value of functional magnetic resonance imaging (fMRI) in a patient with phantom limb pain following traumatic amputation of the right arm.
  • After failure with medication, resection of stump neurinoma, and spinal cord stimulation, fMRI with evidence of cortical reorganization was performed.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 2001 Nov;124(Pt 11):2268-77 [11673327.001]
  • [Cites] Neurosurgery. 2001 Mar;48(3):681-7; discussion 687-8 [11270562.001]
  • [Cites] Surg Neurol. 1998 Aug;50(2):110-20; discussion 120-1 [9701116.001]
  • [Cites] Stereotact Funct Neurosurg. 2001;77(1-4):172-6 [12378072.001]
  • [Cites] Pain. 1975 Dec;1(4):379-84 [800639.001]
  • [Cites] J Neurosci. 1996 Dec 1;16(23):7688-98 [8922425.001]
  • (PMID = 17846735.001).
  • [ISSN] 0028-2804
  • [Journal-full-title] Der Nervenarzt
  • [ISO-abbreviation] Nervenarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. Silva SR, Tempone AJ, Silva TP, Costa MR, Pereira GM, Lara FA, Pessolani MC, Esquenazi D: Mycobacterium leprae downregulates the expression of PHEX in Schwann cells and osteoblasts. Mem Inst Oswaldo Cruz; 2010 Aug;105(5):627-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mycobacterium leprae downregulates the expression of PHEX in Schwann cells and osteoblasts.
  • Phosphate-regulating gene with homologies to endopeptidase on the X chromosome (PHEX) is a Zn-metalloendopeptidase, which is abundantly expressed in osteoblasts and many other cell types, such as Schwann cells, and has been implicated in phosphate metabolism and X-linked rickets.
  • Here, we demonstrate that Mycobacterium leprae stimulation downregulates PHEX transcription and protein expression in a human schwannoma cell line (ST88-14) and human osteoblast lineage.
  • This is the first report to describe PHEX modulation by an infectious agent.
  • [MeSH-major] Leprosy / metabolism. Mycobacterium leprae. Osteoblasts / enzymology. Schwann Cells / enzymology

  • MedlinePlus Health Information. consumer health - Mycobacterial Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20835608.001).
  • [ISSN] 1678-8060
  • [Journal-full-title] Memórias do Instituto Oswaldo Cruz
  • [ISO-abbreviation] Mem. Inst. Oswaldo Cruz
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] EC 3.4.24.- / PHEX Phosphate Regulating Neutral Endopeptidase
  •  go-up   go-down


28. Lee HK, Seo IA, Suh DJ, Hong JI, Yoo YH, Park HT: Interleukin-6 is required for the early induction of glial fibrillary acidic protein in Schwann cells during Wallerian degeneration. J Neurochem; 2009 Feb;108(3):776-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-6 is required for the early induction of glial fibrillary acidic protein in Schwann cells during Wallerian degeneration.
  • During peripheral nerve regeneration, a nerve injury-induced up-regulation of cytokines and growth factors accompanies STAT3 activation in sensory neurons and Schwann cells (SCs) even though its molecular details and functions are unknown.
  • We then analyzed the ligands and functions of STAT3 activation in RT4 schwannoma cells and adult SCs in vitro and in vivo.
  • [MeSH-major] Glial Fibrillary Acidic Protein / biosynthesis. Interleukin-6 / physiology. Schwann Cells / metabolism. Wallerian Degeneration / metabolism
  • [MeSH-minor] Animals. Blotting, Western. Cell Line. Ciliary Neurotrophic Factor / pharmacology. Cytokine Receptor gp130 / physiology. Cytokines / biosynthesis. Cytokines / genetics. Fluorescent Antibody Technique. Genes, Reporter / drug effects. Leukemia Inhibitory Factor / pharmacology. Luciferases / biosynthesis. Luciferases / genetics. Mice. Mice, Knockout. Phosphorylation. RNA, Small Interfering / pharmacology. Rats. Reverse Transcriptase Polymerase Chain Reaction. STAT3 Transcription Factor / biosynthesis. STAT3 Transcription Factor / genetics. Sciatic Nerve / cytology. Sciatic Nerve / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19187095.001).
  • [ISSN] 1471-4159
  • [Journal-full-title] Journal of neurochemistry
  • [ISO-abbreviation] J. Neurochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ciliary Neurotrophic Factor; 0 / Cytokines; 0 / Glial Fibrillary Acidic Protein; 0 / Interleukin-6; 0 / Leukemia Inhibitory Factor; 0 / RNA, Small Interfering; 0 / STAT3 Transcription Factor; 0 / Stat3 protein, rat; 133483-10-0 / Cytokine Receptor gp130; EC 1.13.12.- / Luciferases
  •  go-up   go-down


29. Somefun OA, Giwa OS, Bamgboye BA, Okeke-Igbokwe II, Azeez AA: Vestibular disorders among adults in a tertiary hospital in Lagos, Nigeria. Eur Arch Otorhinolaryngol; 2010 Oct;267(10):1515-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To a large number of practitioners, the treatment of dizziness remains the same irrespective of the etiology, i.e., anti-vertiginous drugs.
  • General physical and neuro-otological examinations were done.
  • Peripheral vestibular disorders are common of which benign paroxysmal positional vertigo (BPPV) was seen in 29 (28.4%), Meniere's disease in 22 (21.6%), recurrent vestibulopathy in 20 (19.6%), cervical vertigo in 18 (17.6%), psychogenic vertigo in 2 (2%), vestibular schwannoma, barotraumas and drug-induced vertigo in 1 (1%), respectively, central vestibular disorders of vascular origin 2 (2%), vertebrobasilar insufficiency in 1 (1%), post-traumatic vertigo in 3 (3%) and unknown in 2 (2%).
  • Pre-referral anti-vertiginous medication is common among general practitioners.
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Benign Paroxysmal Positional Vertigo. Cohort Studies. Female. Hearing Loss / diagnosis. Hearing Loss / epidemiology. Hearing Loss / therapy. Hospitalization. Humans. Male. Middle Aged. Nigeria. Risk Factors. Severity of Illness Index. Vertigo / diagnosis. Vertigo / epidemiology. Vertigo / therapy. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 2009 May 25;169(10):938-44 [19468085.001]
  • [Cites] Otolaryngol Pol. 2008;62(3):283-7 [18652150.001]
  • [Cites] J Laryngol Otol. 1972 Sep;86(9):917-25 [5070302.001]
  • [Cites] Br J Hosp Med. 1996 Nov 20-Dec 10;56(10):519-20, 537-41 [8958404.001]
  • [Cites] Aging Clin Exp Res. 2009 Apr;21(2):136-42 [19448385.001]
  • [Cites] J Laryngol Otol. 2005 May;119(5):366-70 [15949100.001]
  • [Cites] Otolaryngol Head Neck Surg. 1990 Feb;102(2):111-7 [2113234.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1997 Apr;22(2):106-10 [9160919.001]
  • [Cites] J Laryngol Otol. 1979 Aug;93(8):809-15 [490032.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2005 Mar;60(3):404-6 [15860483.001]
  • [Cites] Acta Otolaryngol. 1998 Jul;118(4):474-8 [9726669.001]
  • [Cites] Arch Gerontol Geriatr. 2009 Jul-Aug;49(1):113-7 [18619684.001]
  • [Cites] Lancet. 2008 Aug 2;372(9636):406-14 [18675691.001]
  • [Cites] Acad Emerg Med. 2008 Aug;15(8):744-50 [18638027.001]
  • [Cites] Niger Med J. 1978 Nov;8(6):579-80 [753061.001]
  • [Cites] J Laryngol Otol. 2003 Aug;117(8):599-604 [12956912.001]
  • [Cites] Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1994 Oct;109(2):173-89 [7881818.001]
  • [Cites] Niger Med J. 1979 Jan;9(1):52-7 [463341.001]
  • [Cites] Laryngoscope. 1983 Nov;93(11 Pt 1):1419-24 [6633113.001]
  • [Cites] Otolaryngol Pol. 1995;49(4):332-8 [8532353.001]
  • [Cites] Toxicol Rev. 2006;25(1):55-69 [16856769.001]
  • [Cites] J Laryngol Otol. 1984 Aug;98(8):775-9 [6470573.001]
  • [Cites] Niger J Med. 2003 Jul-Sep;12(3):140-4 [14737984.001]
  • [Cites] J Laryngol Otol. 1982 Sep;96(9):847-55 [7153647.001]
  • [Cites] Otol Neurotol. 2004 Jul;25(4):559-69 [15241236.001]
  • [Cites] West J Med. 1992 Nov;157(5):544-53 [1441496.001]
  • [Cites] Trop Doct. 1992 Jan;22(1):10-3 [1542941.001]
  • [Cites] Otolaryngol Head Neck Surg. 1994 Nov;111(5):571-4 [7970794.001]
  • [Cites] J Otolaryngol. 1986 Apr;15(2):101-4 [3712537.001]
  • [Cites] Otolaryngol Head Neck Surg. 1984 Dec;92(6):649-55 [6440083.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2007 Dec;264(12):1399-403 [17610076.001]
  • [Cites] J Psychosom Res. 2006 Apr;60(4):395-401 [16581364.001]
  • (PMID = 20464409.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


30. Clark MK, Scott SA, Wojtkowiak J, Chirco R, Mathieu P, Reiners JJ Jr, Mattingly RR, Borch RF, Gibbs RA: Synthesis, biochemical, and cellular evaluation of farnesyl monophosphate prodrugs as farnesyltransferase inhibitors. J Med Chem; 2007 Jul 12;50(14):3274-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Certain farnesyl diphosphate (FPP) analogs are potent inhibitors of the potential anticancer drug target protein farnesyltransferase (FTase), but these compounds are not suitable as drug candidates.
  • The effects of the prodrug 5b (a derivative of 3-allylfarnesyl monophosphate) have been evaluated on prenylation of RhoB and on the cell cycle in a human malignant schwannoma cell line (STS-26T).
  • In combination treatments, 1-3 microM 5b plus 1 microM lovastatin induced a significant inhibition of RhoB prenylation, and a combination of these drugs at 1 microM each also resulted in significant cell cycle arrest in G1.
  • Indeed, combinations as low as 50 nM lovastatin + 1 microM 5c or 250 nM lovastatin + 50 nM 5c were highly cytostatic in STS-26T cell culture.
  • [MeSH-minor] Cell Line. Cell Proliferation / drug effects. Chromatography, High Pressure Liquid. Magnetic Resonance Spectroscopy. Spectrometry, Mass, Electrospray Ionization

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17555307.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 34619; United States / NCI NIH HHS / CA / P30 CA21368; United States / NIEHS NIH HHS / ES / P30 ES06639; United States / NIEHS NIH HHS / ES / T32 ES012163
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Polyisoprenyl Phosphates; 0 / Prodrugs; 15416-91-8 / farnesyl monophosphate; EC 2.5.1.29 / Farnesyltranstransferase
  •  go-up   go-down


31. Pereira RM, Calegari-Silva TC, Hernandez MO, Saliba AM, Redner P, Pessolani MC, Sarno EN, Sampaio EP, Lopes UG: Mycobacterium leprae induces NF-kappaB-dependent transcription repression in human Schwann cells. Biochem Biophys Res Commun; 2005 Sep 16;335(1):20-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mycobacterium leprae induces NF-kappaB-dependent transcription repression in human Schwann cells.
  • Mycobacterium leprae, the causative agent of leprosy, invades peripheral nerve Schwann cells, resulting in deformities associated with this disease.
  • We aimed in this work to investigate NF-kappaB signaling pathways in the human ST88-14 Schwannoma cell line infected with M. leprae.
  • Gel shift and supershift assays indicate that two NF-kappaB dimers, p65/p50 and p50/p50, translocate to the nucleus in Schwann cells treated with lethally irradiated M. leprae.
  • Moreover, thalidomide inhibited p50 homodimer nuclear translocation induced by M. leprae and consequently rescues Schwann cells from NF-kappaB-dependent transcriptional repression.
  • Here, we report for the first time that M. leprae induces NF-kappaB activation in Schwann cells and thalidomide is able to modulate this activation.
  • [MeSH-major] Mycobacterium leprae / physiology. NF-kappa B / metabolism. Schwann Cells / metabolism. Schwann Cells / microbiology. Transcription, Genetic
  • [MeSH-minor] Active Transport, Cell Nucleus. Cell Nucleus / metabolism. Down-Regulation. Humans. I-kappa B Proteins / metabolism. Lipopolysaccharides / pharmacology. Thalidomide / pharmacology. Tumor Necrosis Factor-alpha / pharmacology

  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16055086.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / I-kappa B Proteins; 0 / Lipopolysaccharides; 0 / NF-kappa B; 0 / Tumor Necrosis Factor-alpha; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


32. Ghosh S, Weiss M, Streeter O, Sinha U, Commins D, Chen TC: Drop metastasis from sinonasal undifferentiated carcinoma: clinical implications. Spine (Phila Pa 1976); 2001 Jul 1;26(13):1486-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To elucidate the mechanisms by which metastatic disease invades the spinal axis, and to discuss the possibility of spinal drop metastasis from head and neck tumors that invade the dura.
  • METHODS: This report is based on a single patient treated by a multidisciplinary team from the departments of neurosurgery, otolaryngology, and radiation oncology at the University of Southern California School of Medicine.
  • At the time of surgery, the tumor was noted to violate the dura and arachnoid along the subfrontal plane.
  • Imaging of the spine showed an intradural, extramedullary tumor at T2 consistent with a schwannoma or meningioma.
  • The patient underwent a laminectomy and tumor resection, which showed poorly differentiated sinonasal carcinoma.
  • The primary tumor likely seeded the cerebrospinal fluid, thus resulting in drop metastasis.

  • Genetic Alliance. consumer health - Sinonasal undifferentiated carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11458156.001).
  • [ISSN] 0362-2436
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Greenson JK: Gastrointestinal stromal tumors and other mesenchymal lesions of the gut. Mod Pathol; 2003 Apr;16(4):366-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Along with this understanding comes an exciting new drug therapy (Gleevec) that for the first time offers real hope to patients with malignant stromal tumors.
  • Although the most important tool needed to diagnose a GIST is still a hematoxylin and eosin-stained section, a confirmatory CD117 stain is recommended (and may be required for drug therapy).
  • True smooth muscle tumors, inflammatory fibroid polyps, fibromatoses, schwannomas, inflammatory myofibroblastic tumors, and solitary fibrous tumors all enter into the differential diagnosis of GISTs.
  • [MeSH-major] Biomarkers, Tumor / analysis. Gastrointestinal Neoplasms / pathology. Mesoderm / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Benzamides. Diagnosis, Differential. Imatinib Mesylate. Immunohistochemistry. Molecular Biology. Piperazines / therapeutic use. Prognosis. Pyrimidines / therapeutic use

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12692202.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 55
  •  go-up   go-down


34. Murcia PR, Delhon G, González MJ, Vilas M, Ramos-Vara JA, De Las Heras M, Nordhausen RW, Uzal FA: Cluster of cases of malignant schwannoma in cattle. Vet Rec; 2008 Sep 13;163(11):331-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cluster of cases of malignant schwannoma in cattle.
  • Five cases of this cluster were studied and a diagnosis of malignant schwannoma was established.
  • Electron microscopy (em) of tumour samples from three of the animals revealed intracytoplasmic or interstitial structures resembling retroviral particles.
  • Attempts to isolate a viral agent from the tumours were unsuccessful but the epidemiological data and the em findings suggest a viral aetiology.
  • [MeSH-major] Cattle Diseases / pathology. Neurilemmoma / veterinary. Spinal Cord Neoplasms / veterinary
  • [MeSH-minor] Animals. Argentina. Cattle. Female. Microscopy, Electron / veterinary. Retroviridae / ultrastructure. Spinal Nerve Roots / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18791208.001).
  • [ISSN] 0042-4900
  • [Journal-full-title] The Veterinary record
  • [ISO-abbreviation] Vet. Rec.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


35. Khismatullina NA, Iusupov RKh, Selimov MA, Ianbarisova SR: [Development of a rapid method of immunologic monitoring during pregnancy]. Vopr Virusol; 2001 Sep-Oct;46(5):45-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors validate the efficiency of enzyme-linked immunoassay (ELISA) for rapid diagnosis of rabies and titration of specific antibodies and of the method of isolation of field rabies strains in the rat Gasser's node neurinoma cells.
  • Highly active specific diagnostic agents for ELISA and immunofluorescent test based on sheep immunoglobulins have been created for detection of the rabies agent in pathological material from different animals and humans.
  • [MeSH-minor] Animals. Antibodies, Viral / analysis. Female. Humans. Pregnancy. Rabies virus / immunology. Rats

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Rabies.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11715711.001).
  • [ISSN] 0507-4088
  • [Journal-full-title] Voprosy virusologii
  • [ISO-abbreviation] Vopr. Virusol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


36. Bischoff B, Romstöck J, Fahlbusch R, Buchfelder M, Strauss C: Intraoperative brainstem auditory evoked potential pattern and perioperative vasoactive treatment for hearing preservation in vestibular schwannoma surgery. J Neurol Neurosurg Psychiatry; 2008 Feb;79(2):170-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative brainstem auditory evoked potential pattern and perioperative vasoactive treatment for hearing preservation in vestibular schwannoma surgery.
  • OBJECTIVE: In vestibular schwannoma surgery, four different intraoperative brainstem auditory evoked potential (BAEP) patterns (stable BAEP, abrupt loss, irreversible progressive loss, reversible loss) can be identified and correlated with postoperative hearing outcome.
  • METHODS: A retrospective analysis was performed in 92 patients operated on for vestibular schwannoma between 1997 and 2005.
  • Between 1997 and 2001, only patients with reversible loss of BAEP received vasoactive medication.
  • RESULTS: All 30 patients with reversible loss of BAEP received medication, and postoperative hearing preservation was documented in 21 patients.
  • [MeSH-major] Evoked Potentials, Auditory, Brain Stem / physiology. Hearing / physiology. Monitoring, Intraoperative. Neuroma, Acoustic / surgery. Vasodilator Agents / therapeutic use
  • [MeSH-minor] Adult. Brain Stem / physiopathology. Cochlear Nerve / blood supply. Cochlear Nerve / injuries. Deafness / drug therapy. Deafness / physiopathology. Female. Follow-Up Studies. Hearing Loss, Sensorineural / drug therapy. Hearing Loss, Sensorineural / physiopathology. Humans. Hydroxyethyl Starch Derivatives / therapeutic use. Ischemia / drug therapy. Ischemia / physiopathology. Male. Microcirculation / physiopathology. Middle Aged. Nimodipine / therapeutic use. Postoperative Complications / drug therapy. Postoperative Complications / physiopathology. Retrospective Studies

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578855.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydroxyethyl Starch Derivatives; 0 / Vasodilator Agents; 57WA9QZ5WH / Nimodipine
  •  go-up   go-down


37. Hanemann CO, Evans DG: News on the genetics, epidemiology, medical care and translational research of Schwannomas. J Neurol; 2006 Dec;253(12):1533-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] News on the genetics, epidemiology, medical care and translational research of Schwannomas.
  • Recent years have seen substantial news and updates in the genetics and diagnosis of schwannomas, even a new hereditary disease with schwannomas; Schwannomatosis has been defined.
  • These developments have consequently led to better evaluation of the incidence of schwannomas.
  • Although there has also been progress in the treatment of schwannomas especially in the field of radiation therapy, hereditary diseases with multiple tumours still represent a therapeutic dilemma.
  • NF2 in particular still causes major morbidity and mortality owing to the neurological deficit of multiple tumour disease and deafness caused by vestibular nerve involvement.
  • Thus there has been great enthusiasm about disease models in the hope that translational research will give rise to new therapies.
  • [MeSH-major] Disease Models, Animal. Genes, Neurofibromatosis 2. Neurilemmoma. Research
  • [MeSH-minor] Animals. Disease Progression. Humans. Mice. Mice, Knockout

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2002 Dec 1;11(25):3179-89 [12444102.001]
  • [Cites] Q J Med. 1992 Aug;84(304):603-18 [1484939.001]
  • [Cites] Genet Epidemiol. 2003 May;24(4):265-72 [12687643.001]
  • [Cites] Laryngoscope. 1999 May;109(5):736-40 [10334223.001]
  • [Cites] Br J Cancer. 2000 Feb;82(4):998 [10732777.001]
  • [Cites] Mol Cell. 2003 Oct;12 (4):841-9 [14580336.001]
  • [Cites] Hum Gene Ther. 2006 Jan;17(1):20-30 [16409122.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] J Med Genet. 2003 Nov;40(11):802-6 [14627667.001]
  • [Cites] AJR Am J Roentgenol. 1995 Oct;165(4):951-5 [7676998.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):89-92 [10973256.001]
  • [Cites] Arch Neurol. 2005 Apr;62(4):674-5 [15824272.001]
  • [Cites] J Med Genet. 2003 Feb;40(2):109-14 [12566519.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):75-81 [16111574.001]
  • [Cites] J Neurosurg. 2002 Feb;96(2):223-8 [11838794.001]
  • [Cites] Neurosurgery. 1998 Feb;42(2):279-89; discussion 289-90 [9482178.001]
  • [Cites] Zentralbl Allg Pathol. 1983;127(5-6):305-14 [6410615.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Mar 7;302(2):238-45 [12604337.001]
  • [Cites] Neurobiol Dis. 2005 Jun-Jul;19(1-2):1-9 [15837555.001]
  • [Cites] Neoplasia. 2002 Nov-Dec;4(6):501-9 [12407444.001]
  • [Cites] Cancer Biol Ther. 2005 Apr;4(4):379-81 [15846074.001]
  • [Cites] J Neuropathol Exp Neurol. 1993 Mar;52(2):106-13 [8440992.001]
  • [Cites] J Med Genet. 1992 Dec;29(12 ):841-6 [1479598.001]
  • [Cites] Otol Neurotol. 2005 Jan;26(1):93-7 [15699726.001]
  • [Cites] Otol Neurotol. 2004 Sep;25(5):811-7 [15354016.001]
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] Otol Neurotol. 2004 Mar;25(2):150-4 [15021775.001]
  • [Cites] Am J Hum Genet. 2002 Oct;71(4):715-23 [12235555.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):248-60; discussion 260-2 [9007856.001]
  • [Cites] Eur J Nucl Med. 2001 Oct;28(10 ):1541-51 [11685498.001]
  • [Cites] Am J Hum Genet. 1996 Aug;59(2):331-42 [8755919.001]
  • [Cites] Neurosurgery. 1997 Apr;40(4):684-94; discussion 694-5 [9092841.001]
  • [Cites] Acta Otolaryngol. 1997 Jul;117(4):482-9 [9288200.001]
  • [Cites] Am J Hum Genet. 1996 Sep;59(3):529-39 [8751853.001]
  • [Cites] Hum Mol Genet. 2003 Jun 1;12(11):1211-21 [12761036.001]
  • [Cites] J Med Genet. 2000 Dec;37(12):897-904 [11106352.001]
  • [Cites] Cancer J. 2004 Jan-Feb;10(1):20-6 [15000491.001]
  • [Cites] J Neurosurg. 1991 Feb;74(2):248-53 [1846409.001]
  • [Cites] J Neurosurg. 1989 Dec;71(6):810-4 [2585070.001]
  • [Cites] Neurobiol Dis. 1998 Jul;5(1):55-64 [9702788.001]
  • [Cites] Neurobiol Dis. 2000 Aug;7(4):483-91 [10964617.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):269-71 [16421138.001]
  • [Cites] Otol Neurotol. 2005 Jan;26(1):86-92 [15699725.001]
  • [Cites] Brain. 2002 May;125(Pt 5):996-1004 [11960890.001]
  • [Cites] Neurology. 2005 Jun 14;64(11):1838-45 [15955931.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1997 Apr;62(4):361-6 [9120449.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1288-93 [12933938.001]
  • [Cites] Neurology. 2006 Mar 14;66(5):730-2 [16534111.001]
  • [Cites] J Neurosurg Spine. 2005 May;2(5):574-9 [15945431.001]
  • [Cites] Otol Neurotol. 2005 Jan;26(1):98-101 [15699727.001]
  • [Cites] Radiology. 2001 Feb;218(2):434-42 [11161159.001]
  • [Cites] Neurology. 2000 Jan 11;54(1):71-6 [10636128.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 23;335(2):385-92 [16083858.001]
  • [Cites] Acta Otolaryngol Suppl. 2000;542:18-21 [10897394.001]
  • [Cites] Genes Dev. 1998 Apr 15;12(8):1121-33 [9553042.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):352-63 [12946024.001]
  • [Cites] Nat Rev Drug Discov. 2003 Apr;2(4):296-313 [12669029.001]
  • [Cites] Br J Neurosurg. 2005 Feb;19(1):5-12 [16147576.001]
  • [Cites] Otolaryngol Clin North Am. 2002 Apr;35(2):393-404, viii [12391625.001]
  • [Cites] J Med Genet. 2003 Jun;40(6):459-63 [12807969.001]
  • [Cites] Hum Mol Genet. 2002 Jan 1;11(1):69-76 [11773000.001]
  • [Cites] Am J Hum Genet. 2004 Aug;75(2):231-9 [15190457.001]
  • [Cites] Curr Opin Pharmacol. 2005 Aug;5(4):350-6 [15955734.001]
  • (PMID = 17219030.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 63
  •  go-up   go-down


38. Mrak RE: The Big Eye in the 21st century: the role of electron microscopy in modern diagnostic neuropathology. J Neuropathol Exp Neurol; 2002 Dec;61(12):1027-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Big Eye in the 21st century: the role of electron microscopy in modern diagnostic neuropathology.
  • Electron microscopy (EM) remains a powerful and even essential tool in modern diagnostic neuropathology. tumors are still encountered that defy histological or immunohistochemical classification, and EM can often provide answers in these cases.
  • Tumors of the CNS for which EM is useful include unusual or atypical variants of meningioma, ependymoma, and schwannoma; oligodendroglioma-like tumors composed of small "clear" cells; and small "blue cell" tumors of childhood.
  • EM is also important in the evaluation of certain congenital, inherited and metabolic diseases-including ceroid lipofuscinoses, CADASIL syndrome, certain myopathies, and mitochondrial encephalomyopathies--and of certain toxic and drug-induced peripheral neuropathies.
  • An important application of EM is its utility in initiating a workup of an atypical tumor or metabolic condition, for which clinical and histological clues point in no obvious direction.
  • In these situations, EM may provide either an answer outright (including answers to questions not asked) or important clues that guide further workup and narrow the range of diagnostic possibilities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12484565.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 60
  •  go-up   go-down


39. Kinoshita M, Izumoto S, Oshino S, Nonaka M, Moriuchi S, Maruno M, Yoshimine T: Primary malignant lymphoma of the trigeminal region treated with rapid infusion of high-dose MTX and radiation: case report and review of the literature. Surg Neurol; 2003 Oct;60(4):343-8; discussion 348
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Though the tumor responds well to radiation and chemotherapy, the prognosis of primary CNS lymphoma remains poor.
  • We report a case of primary lymphoma of Meckel's cave mimicking a trigeminal schwannoma radiographically, which achieved complete remission through use of rapid high-dose MTX therapy and radiation therapy.
  • Magnetic resonance imaging (MRI) revealed a mass lesion in the left side of Meckel's cave, with extension into the cerebellopontine angle and the infratemporal fossa through the foramen ovale, suggesting trigeminal schwannoma.
  • However, the patient suffered radiologically inexplicable progressive cranial nerve palsy, which suggested malignant disease.
  • MRI and CSF disclosed malignant tumor dissemination; biopsy revealed malignant lymphoma.
  • CONCLUSIONS: This case, which included atypical presentation of malignant lymphoma, illustrates the importance of including malignant lymphoma in the differential diagnosis of CP-angle and Meckel's cave tumor.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Cranial Nerve Neoplasms / drug therapy. Cranial Nerve Neoplasms / radiotherapy. Lymphoma / drug therapy. Lymphoma / radiotherapy. Methotrexate / administration & dosage. Trigeminal Nerve Diseases / drug therapy. Trigeminal Nerve Diseases / radiotherapy. Trigeminal Neuralgia / etiology
  • [MeSH-minor] Chemotherapy, Adjuvant. Cranial Irradiation. Drug Administration Schedule. Humans. Infusions, Intravenous. Magnetic Resonance Imaging. Male. Middle Aged. Radiotherapy, Adjuvant. Spine / radiation effects. Treatment Outcome

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Trigeminal Neuralgia.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14505860.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 18
  •  go-up   go-down


40. Hashimoto H, Messerli SM, Sudo T, Maruta H: Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines. Drug Discov Ther; 2009 Dec;3(6):243-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines.
  • However, its anti-cancer mechanism still remained to be clarified at the molecular levels, that would determine the specific type of cancers susceptible to this drug.
  • The first hint towards its anti-PAK1 potential was a recent finding that Ivermectin at its sublethal doses dramatically reduces the litter size (number of eggs laid) of the tiny nematode C. elegans.
  • Interestingly, either a PAK1-deficiency (gene knock-out) or treatment with natural anti-PAK1 products such as CAPE (caffeic acid phenethyl ester) and ARC (artepillin C), the major anti-cancer ingredients in propolis, also causes the exactly same effect on this nematode, suggesting the possibility that the kinase PAK1 might be a new target of Ivermectin.
  • Here we demonstrate for the first time that Ivermectin blocks the oncogenic kinase PAK1 in human ovarian cancer and NF2-deficient Schwannoma cell lines to suppress their PAK1-dependent growth in cell culture, with the IC50 between 5-20 μM depending on cell lines.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22495656.001).
  • [ISSN] 1881-7831
  • [Journal-full-title] Drug discoveries & therapeutics
  • [ISO-abbreviation] Drug Discov Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


41. Hilton DA, Ristic N, Hanemann CO: Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ. Histopathology; 2009 Dec;55(6):744-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ.
  • AIMS: Schwannomas are common tumours that may be multiple in neurofibromatosis type 2, when they may be difficult to treat without significant morbidity using surgery and radiosurgery.
  • Previous in vitro work has suggested that merlin loss is associated with activation of the JNK/JUN, PI3K/AKT and MEK/ERK pathways and that these pathways may be susceptible to pharmacological inhibition.
  • The aim was to investigate the expression of proteins involved in these pathways in human schwannomas in situ.
  • METHODS AND RESULTS: Immunohistochemistry using antibodies to AKT, pAKT, MEK, pMEK, ERK, pERK, JUN and pJUN was applied to 16 schwannomas (sporadic and NF2), and the results were compared with those seen in traumatic neuromas.
  • Increased expression of pMEK, pERK and pJUN was seen in the schwannomas samples and of pAKT in schwannomas and controls.
  • CONCLUSIONS: These findings provide further direct evidence for activation of the JNK/JUN, PI3K/AKT and MEK/ERK signalling pathways in schwannomas and support the development of therapeutic agents directed against these pathways for the treatment of this group of tumours.
  • [MeSH-major] Central Nervous System Neoplasms / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. JNK Mitogen-Activated Protein Kinases / metabolism. Neurilemmoma / metabolism. Peripheral Nervous System Neoplasms / metabolism. Proto-Oncogene Proteins c-akt / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19919586.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  •  go-up   go-down


42. Scheller C, Richter HP, Engelhardt M, Köenig R, Antoniadis G: The influence of prophylactic vasoactive treatment on cochlear and facial nerve functions after vestibular schwannoma surgery: a prospective and open-label randomized pilot study. Neurosurgery; 2007 Jul;61(1):92-7; discussion 97-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of prophylactic vasoactive treatment on cochlear and facial nerve functions after vestibular schwannoma surgery: a prospective and open-label randomized pilot study.
  • OBJECTIVE: Facial nerve paresis and hearing loss are common complications after vestibular schwannoma surgery.
  • This prospective and open-label randomized pilot study is the first study of a prophylactic vasoactive treatment in vestibular schwannoma surgery.
  • The other group (n = 16) did not receive preoperative medication.
  • However, when electrophysiological signs of a deterioration of facial or cochlear nerve function were detected in the group of patients without medication, vasoactive treatment was started immediately.
  • RESULTS: Despite the limited number of patients, our results were significant using the Fisher's exact test (small no. of patients) for a better outcome after vestibular schwannoma surgery for both hearing (P = 0.041) and facial nerve (P = 0.045) preservation in the group of patients who received a prophylactic vasoactive treatment.
  • CONCLUSION: Prophylactic vasoactive treatment consisting of nimodipine and hydroxyethylstarch shows significantly better results concerning preservation of the facial and cochlear nerve function in vestibular schwannoma surgery.
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant / methods. Cranial Nerve Neoplasms / surgery. Humans. Male. Middle Aged. Neurilemmoma / surgery. Pilot Projects. Treatment Outcome. Vasodilator Agents / administration & dosage

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621023.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vasodilator Agents; 57WA9QZ5WH / Nimodipine
  •  go-up   go-down


43. Dumas G, Perrin P, Morel N, N'Guyen DQ, Schmerber S: [Skull vibratory test in partial vestibular lesions--influence of the stimulus frequency on the nystagmus direction]. Rev Laryngol Otol Rhinol (Bord); 2005;126(4):235-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Le test vibratoire osseux crânien dans les lésions vestibulaires périphériques partielles--influence de la fréquence du stimulus sur le sens du nystagmus.
  • To appreciate the degree of vestibular deafferentation (extended to high frequencies) provoked by gentamicin labyrinthectomy and its efficiency in Meniere's disease.
  • SVN is not correlated with the side of the lesion in 20% of Meniere's disease, in 8% of vestibular neuritis and in 6% of vestibular schwannoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Anti-Bacterial Agents / therapeutic use. Caloric Tests / methods. Case-Control Studies. Female. Gentamicins / therapeutic use. Head. Humans. Male. Meniere Disease / diagnosis. Meniere Disease / drug therapy. Meniere Disease / pathology. Meniere Disease / physiopathology. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16496550.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Gentamicins
  •  go-up   go-down


44. Kamiya H, Nakamura J, Hamada Y, Nakashima E, Naruse K, Kato K, Yasuda Y, Hotta N: Polyol pathway and protein kinase C activity of rat Schwannoma cells. Diabetes Metab Res Rev; 2003 Mar-Apr;19(2):131-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polyol pathway and protein kinase C activity of rat Schwannoma cells.
  • However, it remains unclear whether PKC activities in neural cells such as Schwann cells are increased, decreased, or unchanged.
  • This study investigated the effects of high glucose and increased polyol pathway activity on neural cell growth and PKC activities.
  • METHODS: Rat Schwannoma cells were cultured in 5.5 or 20 mM glucose in the presence or absence of an aldose reductase inhibitor, epalrestat (1 microM) for 14 days.
  • CONCLUSIONS: These results suggest that PKC, especially PKC-alpha activity, is decreased in Schwann cells exposed to high glucose and that this deficit is mediated through polyol pathway hyperactivity.
  • [MeSH-major] Diabetic Neuropathies / enzymology. Neurilemmoma. Polymers / metabolism. Protein Kinase C / metabolism. Rhodanine / analogs & derivatives
  • [MeSH-minor] Aldehyde Reductase / antagonists & inhibitors. Aldehyde Reductase / metabolism. Animals. Cell Division / drug effects. Enzyme Activation / drug effects. Enzyme Inhibitors / pharmacology. Fructose / metabolism. Glucose / pharmacology. Inositol / metabolism. Protein Kinase C beta. Protein Kinase C-alpha. Protein Kinase C-delta. Rats. Sorbitol / metabolism. Thiazolidines. Tumor Cells, Cultured / cytology. Tumor Cells, Cultured / enzymology. Tumor Cells, Cultured / metabolism

  • MedlinePlus Health Information. consumer health - Diabetic Nerve Problems.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RHODANINE .
  • Hazardous Substances Data Bank. D-Sorbitol .
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 John Wiley & Sons, Ltd.
  • (PMID = 12673781.001).
  • [ISSN] 1520-7552
  • [Journal-full-title] Diabetes/metabolism research and reviews
  • [ISO-abbreviation] Diabetes Metab. Res. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Polymers; 0 / Thiazolidines; 0 / polyol; 30237-26-4 / Fructose; 424DV0807X / epalrestat; 4L6452S749 / Inositol; 506T60A25R / Sorbitol; 7O50LKL2G8 / Rhodanine; EC 1.1.1.21 / Aldehyde Reductase; EC 2.7.1.- / Prkcd protein, rat; EC 2.7.1.- / protein kinase C gamma; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C beta; EC 2.7.11.13 / Protein Kinase C-alpha; EC 2.7.11.13 / Protein Kinase C-delta; IY9XDZ35W2 / Glucose
  •  go-up   go-down


45. Schöfl C, Schöfl-Siegert B, Karstens JH, Bremer M, Lenarz T, Cuarezma JS, Samii M, von zur Mühlen A, Brabant G: Falsely low serum prolactin in two cases of invasive macroprolactinoma. Pituitary; 2002;5(4):261-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The differential diagnosis of tumors at the base of the skull comprises meningiomas, neurinomas, gliomas, metastatic carcinomas, chordomas, epidermoids, and pituitary adenomas.
  • About half of the pituitary adenomas are prolactinomas which are unique in a sense that medical therapy causes rapid tumor shrinkage and symptomatic improvement.
  • A massive invasively growing tumor was demonstrated on a cranial MRI.
  • Dopamine agonist therapy was initiated under which PRL levels declined in parallel with tumor size.
  • Cranial MRI showed a large tumor at the base of the skull.
  • Under dopamine agonist therapy, PRL declined to normal values, tumor size decreased and cranial nerve palsies disappeared.
  • Serial dilutions of serum PRL samples is, therefore, mandatory in the diagnostic work-up of patients with large invasive tumors at the base of the skull.
  • This avoids unnecessary aggressive and dangerous treatment like surgery or radiotherapy in cases where pharmacological treatment may be the choice.
  • [MeSH-minor] Adult. Dopamine Agonists / therapeutic use. Ergolines / therapeutic use. False Negative Reactions. Headache / etiology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Pituitary Function Tests. Skull Base Neoplasms / blood. Skull Base Neoplasms / drug therapy. Skull Base Neoplasms / pathology. Vision Disorders / etiology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 1992 May;13(2):220-40 [1352243.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Mar;44(3):305-9 [8729527.001]
  • [Cites] J Clin Endocrinol Metab. 2000 May;85(5):1789-93 [10843153.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):804-12 [9024719.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2381-5 [9253304.001]
  • [Cites] N Engl J Med. 1985 Sep 12;313(11):656-9 [4022058.001]
  • [Cites] Arch Intern Med. 1993 Sep 27;153(18):2165, 2168 [8379808.001]
  • [Cites] Clin Endocrinol (Oxf). 1991 Mar;34(3):231-5 [2036731.001]
  • [Cites] Neurosurgery. 1998 Apr;42(4):913-5; discussion 915-6 [9574657.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jul;84(7):2518-22 [10404830.001]
  • (PMID = 14558675.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Ergolines; 9002-62-4 / Prolactin; LL60K9J05T / cabergoline
  •  go-up   go-down


46. Cheshire WP, Odell JA, Woodward TA, Wharen RE Jr: Cervical sympathetic neuralgia arising from a schwannoma. Headache; 2007 Mar;47(3):444-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical sympathetic neuralgia arising from a schwannoma.
  • We describe an unusual case of neuropathic pain of the left face and shoulder accompanied by ipsilateral hyperhidrosis caused by a schwannoma of the cervical sympathetic chain.
  • The pain was refractory to analgesic and antimigraine medications but resolved following surgical resection of the T2 schwannoma.
  • [MeSH-major] Autonomic Nervous System Diseases / complications. Face. Nervous System Neoplasms / complications. Neuralgia / etiology. Neurilemmoma / complications. Shoulder


47. Sornmayura P: Gastrointestinal stromal tumors (GISTs): a pathology view point. J Med Assoc Thai; 2009 Jan;92(1):124-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most gastrointestinal soft tissue neoplasms, previously classified as leiomyomas, schwannomas, leiomyoblastomas, or leiomyosarcomas, are now classified as GISTs based on histology, immunohistochemistry, and molecular study.
  • They originate from the stem cells that differentiate toward the pacemaker cell (Interstitial cell of Cajal).
  • Prognostic factors have been identified for GISTs and include tumor size and mitotic rate.
  • Metastatic and inoperable GISTs should be considered the medication with tyrosine kinase inhibitor (imatinib mesylate), which inhibits the c-kit receptor.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / pathology. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Proto-Oncogene Proteins c-kit / genetics. Pyrimidines / therapeutic use
  • [MeSH-minor] Benzamides. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Imatinib Mesylate. Immunohistochemistry / methods. Prognosis

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260254.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 27
  •  go-up   go-down


48. Kramer F, Stöver T, Warnecke A, Diensthuber M, Lenarz T, Wissel K: BDNF mRNA expression is significantly upregulated in vestibular schwannomas and correlates with proliferative activity. J Neurooncol; 2010 May;98(1):31-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BDNF mRNA expression is significantly upregulated in vestibular schwannomas and correlates with proliferative activity.
  • The expression of neurotrophic factors, such as artemin, glial cell line-derived neurotrophic factor (GDNF), neurturin, transforming growth factors (TGF)-beta1/beta2 and brain-derived neurotrophic factor (BDNF), is enhanced in vestibular schwannomas compared to peripheral nerves.
  • Vestibular schwannoma arising from Schwann cells of the vestibular nerve are mostly benign and slow-growing.
  • Most of the pathogenic mechanisms regulating the vestibular schwannoma growth process are unknown.
  • However, molecular mechanisms interfering with regulation of the vestibular schwannoma growth also modulated by mitogenic factors have to be identified.
  • Neurotrophic factors are involved in regulation of developmental processes in neuronal tissues and regeneration after peripheral nerve trauma and also reveal mitogenic effects on glial cell populations.
  • Gene expression profiles of artemin, BDNF, GDNF, TGF-beta1/beta2 and Ret were determined in the vestibular schwannoma in comparison to the peripheral nerve tissues by using semiquantitative RT-PCR.
  • A significant higher BDNF expression was observed in the vestibular schwannoma, whereas gene expression of artemin and GDNF was upregulated in peripheral nerves.
  • The correlation between LI and BDNF, TGF-beta1 and Ret was found to be significant in the vestibular schwannoma.
  • Our results demonstrate a coherence between BDNF expression and proliferative activity in the vestibular schwannoma.
  • Based on these results, we propose a pivotal role for BDNF in modulating the vestibular schwannoma growth.
  • [MeSH-major] Brain-Derived Neurotrophic Factor / genetics. Cell Proliferation. Gene Expression Regulation, Neoplastic / physiology. Neuroma, Acoustic / genetics. RNA, Messenger / metabolism. Up-Regulation / physiology
  • [MeSH-minor] Adult. Aged. Female. Glial Cell Line-Derived Neurotrophic Factor / genetics. Glial Cell Line-Derived Neurotrophic Factor / metabolism. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Nerve Tissue Proteins / genetics. Nerve Tissue Proteins / metabolism. Peripheral Nerves / metabolism. Statistics as Topic / methods. Statistics, Nonparametric. Transforming Growth Factor beta1 / genetics. Transforming Growth Factor beta1 / metabolism. Transforming Growth Factor beta2 / genetics. Transforming Growth Factor beta2 / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngorhinootologie. 2003 May;82(5):318-21 [12800076.001]
  • [Cites] Science. 2002 Nov 8;298(5596):1245-8 [12424382.001]
  • [Cites] Scand J Immunol. 2003 Mar;57(3):279-85 [12641657.001]
  • [Cites] Otol Neurotol. 2007 Dec;28(8):1094-9 [17721409.001]
  • [Cites] Gut. 2003 Sep;52(9):1308-16 [12912863.001]
  • [Cites] Pathol Res Pract. 2007;203(4):245-9 [17317032.001]
  • [Cites] J Neurosci. 2009 Apr 1;29(13):4016-22 [19339597.001]
  • [Cites] CNS Neurol Disord Drug Targets. 2008 Feb;7(1):46-62 [18289031.001]
  • [Cites] J Clin Neurosci. 2009 Mar;16(3):427-36 [19138852.001]
  • [Cites] Cancer Sci. 2009 Jun;100(6):1034-9 [19320641.001]
  • [Cites] Otol Neurotol. 2004 May;25(3):359-65 [15129118.001]
  • [Cites] Trends Neurosci. 2003 May;26(5):232-4 [12744836.001]
  • [Cites] Acta Neuropathol. 1969 Jan 31;12(2):116-40 [5789731.001]
  • [Cites] Otol Neurotol. 2004 Sep;25(5):791-6 [15354013.001]
  • [Cites] Science. 2002 Nov 8;298(5596):1184-6 [12424359.001]
  • [Cites] Otol Neurotol. 2005 Jan;26(1):93-7 [15699726.001]
  • [Cites] Mol Ther. 2009 Jul;17 (7):1173-9 [19293775.001]
  • [Cites] Dig Dis. 2009;27(2):93-101 [19546546.001]
  • [Cites] Mol Endocrinol. 2006 Nov;20(11):2987-98 [16887884.001]
  • [Cites] Cancer Res. 2009 Jun 15;69(12):5099-107 [19509233.001]
  • [Cites] J Neurosci. 1995 Jan;15(1 Pt 1):419-28 [7823146.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):274-81 [16858191.001]
  • [Cites] Neuroscientist. 2009 Feb;15(1):105-16 [19218234.001]
  • [Cites] Mol Cell Neurosci. 2004 Mar;25(3):453-9 [15033173.001]
  • [Cites] J Cell Biol. 1989 Dec;109(6 Pt 2):3419-24 [2557356.001]
  • [Cites] J Immunol. 1984 Oct;133(4):1710-5 [6206131.001]
  • [Cites] J Neurosci Res. 2004 Sep 1;77(5):662-9 [15352212.001]
  • [Cites] J Cell Biol. 1995 Apr;129(2):443-58 [7536747.001]
  • [Cites] Mol Neurobiol. 2006 Feb;33(1):51-62 [16388110.001]
  • [Cites] Otol Neurotol. 2001 Jan;22(1):79-86 [11314722.001]
  • [Cites] Development. 2001 Oct;128(19):3685-95 [11585795.001]
  • [Cites] Acta Otolaryngol. 2002 Oct;122(7):785-7 [12484657.001]
  • [Cites] J Laryngol Otol. 1984 Jul;98(7):685-92 [6747450.001]
  • [Cites] Laryngoscope. 1994 Nov;104(11 Pt 1):1348-52 [7968163.001]
  • [Cites] Nature. 1996 Dec 5;384(6608):467-70 [8945474.001]
  • [Cites] Otol Neurotol. 2005 Jan;26(1):86-92 [15699725.001]
  • [Cites] Injury. 2008 Sep;39 Suppl 3:S37-42 [18723170.001]
  • [Cites] Neuron. 1998 Dec;21(6):1291-302 [9883723.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Dec;123(6):779-83 [11112979.001]
  • [Cites] Am J Otol. 1999 Jan;20(1):65-8 [9918175.001]
  • [Cites] Clin Neuropathol. 2009 Mar-Apr;28(2):105-12 [19353842.001]
  • [Cites] Acta Neurochir (Wien). 1995;134(1-2):35-9 [7668123.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14661-8 [11717413.001]
  • [Cites] Brain Pathol. 2006 Oct;16(4):288-94 [17107598.001]
  • [Cites] J Neurochem. 1999 Jul;73(1):70-8 [10386956.001]
  • [Cites] Neuropathol Appl Neurobiol. 1997 Oct;23(5):380-6 [9364463.001]
  • [Cites] Nucleic Acids Res. 1997 Oct 1;25(19):3957-8 [9380524.001]
  • [Cites] Acta Otolaryngol. 1998 Jun;118(3):337-43 [9655207.001]
  • [Cites] J Neurosci Res. 2007 Jun;85(8):1601-5 [17335080.001]
  • [Cites] J Neurochem. 2005 Sep;94(6):1488-99 [16086701.001]
  • [Cites] Acta Neurochir (Wien). 1995;134(1-2):40-5 [7668124.001]
  • (PMID = 19937367.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ARTN protein, human; 0 / Brain-Derived Neurotrophic Factor; 0 / Glial Cell Line-Derived Neurotrophic Factor; 0 / Ki-67 Antigen; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta1; 0 / Transforming Growth Factor beta2
  •  go-up   go-down


49. Ishimaru A, Hasegawa J, Shinbo K, Arahara T, Kinoshita Y, Shimoyama E, Korehisa M, Oonuki M, Miyazawa T, Itabashi M: [A case of retroperitoneal tumor successfully resected thanks to effective chemotherapy]. Gan To Kagaku Ryoho; 2009 Jun;36(6):1007-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of retroperitoneal tumor successfully resected thanks to effective chemotherapy].
  • First, pathological diagnosis of sarcoma was made by fine needle aspiration, then secondary pathological diagnosis of suspected malignant schwannoma was made by a partial resection.
  • The preoperative diagnosis was difficult in this case, and the tumor had grown too large after partial resection to surgically resect.
  • The effective chemotherapy reduced this tumor enough to allow successful resection.
  • [MeSH-minor] Carcinoma, Embryonal / drug therapy. Carcinoma, Embryonal / pathology. Carcinoma, Embryonal / surgery. Humans. Male. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542726.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


50. Choi SJ, Lee SW, Kim MC, Kwon JY, Park CK, Sung JH, Hong JT, Woo HK: Posteroventral pallidotomy in medically intractable postapoplectic monochorea: case report. Surg Neurol; 2003 Jun;59(6):486-90; discussion 490
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Posteroventral pallidotomy is a widely accepted surgical procedure for treating medically intractable Parkinson's disease and Levo-dopa induced dyskinesia.
  • No other abnormal lesions were shown by magnetic resonance imaging except for a widening of the right cerebellopontine cistern because of an acoustic neurinoma removed 5 years previously.
  • Despite medication with a dopamine antagonist, choreiform movement of the left limb had not improved, and the patient complained of rigidity and slowness of ambulation owing to the side effects of the medicine.
  • A right posteroventral pallidotomy was performed with macrostimulation for a physiologic confirmation of the globus pallidus internus (GPi), which is the conventional target for Parkinson's disease.
  • CONCLUSIONS: Stereotactic surgery for hyperkinetic movement disorders is not as common a procedure as that used for treating Parkinson's disease.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12826351.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


51. Watanabe T, Nagase K, Chosa M, Tobinai K: Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy. Br J Cancer; 2010 Nov 9;103(10):1580-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy.
  • Animal studies suggest that bortezomib predominantly causes pathological changes in Schwann cells.
  • A tractable system to evaluate combination drugs for use with bortezomib is essential to enable continuing clinical benefit from this drug.
  • METHODS: Rat schwannoma cells were pretreated with vincristine (VCR), histone deacetylase inhibitors, anticonvulsants, or a heat-shock protein 90 (HSP90) inhibitor.
  • RESULTS: Aggresome formation was interrupted by VCR, whereas combination treatments with bortezomib involving suberoylanilide hydroxamic acid, 17-allylamino-17-demethoxy-geldanamycin, or clonazepam appear to facilitate the disposal of unfolded proteins via CMA, inducing HSP70 and lysosome-associated membrane protein type 2A (LAMP-2A).
  • CONCLUSIONS: This schwannoma model can be used to test BiPN-reducing drugs.
  • The present data suggest that aggresome formation in Schwann cells is a possible mechanism of BiPN, and drugs that induce HSP70 or LAMP-2A have the potential to alleviate this complication.
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Bortezomib. Cell Division / drug effects. Cell Line, Tumor. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Multiple Myeloma / drug therapy. Multiple Myeloma / pathology. Neurilemmoma. Protein Folding. Proteostasis Deficiencies / pathology. Pyrazines / therapeutic use. Rats. Schwann Cells / cytology. Schwann Cells / pathology

  • Hazardous Substances Data Bank. CLONAZEPAM .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1078-87 [15718306.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):26729-34 [15937340.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10536-44 [16288046.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2A):1065-70 [16619507.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3113-20 [16754936.001]
  • [Cites] EMBO J. 2006 Sep 6;25(17):3921-33 [16917501.001]
  • [Cites] Exp Neurol. 2007 Mar;204(1):317-25 [17214983.001]
  • [Cites] Nature. 2007 Aug 9;448(7154):704-8 [17687326.001]
  • [Cites] J Neurosci. 2007 Nov 28;27(48):13173-80 [18045911.001]
  • [Cites] Cancer Sci. 2008 Jan;99(1):140-4 [17970782.001]
  • [Cites] Rapid Commun Mass Spectrom. 2008;22(4):519-25 [18228243.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2516-20 [17975015.001]
  • [Cites] Neurotoxicology. 2008 Mar;29(2):232-43 [18155769.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1593-9 [18574024.001]
  • [Cites] N Engl J Med. 2008 Aug 28;359(9):906-17 [18753647.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2917-26 [18641367.001]
  • [Cites] J Peripher Nerv Syst. 2008 Dec;13(4):275-82 [19192067.001]
  • [Cites] Br J Haematol. 2009 Mar;144(6):895-903 [19170677.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2488-96 [19318486.001]
  • [Cites] Semin Hematol. 2009 Apr;46(2):166-75 [19389500.001]
  • [Cites] J Cell Biol. 2009 May 18;185(4):629-39 [19433452.001]
  • [Cites] J Neurosci. 2009 Jul 15;29(28):9104-14 [19605647.001]
  • [Cites] J Clin Oncol. 2009 Jul 20;27(21):3518-25 [19528374.001]
  • [Cites] Clin Cancer Res. 2009 Aug 15;15(16):5250-7 [19671864.001]
  • [Cites] Clin Lymphoma Myeloma. 2009 Aug;9(4):278-88 [19717377.001]
  • [Cites] Ther Drug Monit. 2009 Oct;31(5):566-74 [19730280.001]
  • [Cites] EMBO J. 2009 Dec 2;28(23):3758-70 [19875982.001]
  • [Cites] Cancer Sci. 2010 Jan;101(1):196-200 [19817748.001]
  • [Cites] Eur J Pain. 2010 Apr;14(4):343-50 [19695912.001]
  • [Cites] Clin Lymphoma Myeloma Leuk. 2010 Apr;10(2):149-51 [20371450.001]
  • [Cites] Exp Neurol. 2010 Jun;223(2):599-608 [20188093.001]
  • [Cites] Br J Haematol. 2010 Aug;150(4):428-37 [20618338.001]
  • [Cites] J Cell Sci. 2000 Dec;113 Pt 24:4441-50 [11082038.001]
  • [Cites] Trends Cell Biol. 2000 Dec;10(12):524-30 [11121744.001]
  • [Cites] Traffic. 2002 Jun;3(6):388-96 [12010457.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] J Neurosci. 2003 Nov 19;23(33):10672-80 [14627652.001]
  • [Cites] Cell. 2003 Dec 12;115(6):727-38 [14675537.001]
  • [Cites] QJM. 2004 Jan;97(1):33-8 [14702509.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Oct;75(10):5034-8 [368806.001]
  • [Cites] Nat Genet. 1992 Jun;1(3):159-65 [1303228.001]
  • [Cites] Science. 1996 Jul 26;273(5274):501-3 [8662539.001]
  • [Cites] J Cell Biol. 1997 May 19;137(4):825-34 [9151685.001]
  • [Cites] J Cell Biol. 1998 Apr 6;141(1):163-74 [9531556.001]
  • [Cites] Nat Med. 1998 Jul;4(7):755-7 [9662355.001]
  • [Cites] Cell. 1998 Aug 21;94(4):471-80 [9727490.001]
  • [Cites] Science. 1998 Sep 18;281(5384):1851-4 [9743498.001]
  • [Cites] J Cell Biol. 1998 Dec 28;143(7):1883-98 [9864362.001]
  • [Cites] Genes Dev. 1998 Dec 15;12(24):3788-96 [9869631.001]
  • [Cites] J Cell Biol. 1999 Sep 20;146(6):1239-54 [10491388.001]
  • (PMID = 20959823.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoquinones; 0 / Boronic Acids; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 0 / Pyrazines; 4GY0AVT3L4 / tanespimycin; 5PE9FDE8GB / Clonazepam; 69G8BD63PP / Bortezomib
  • [Other-IDs] NLM/ PMC2990589
  •  go-up   go-down


52. Levo H, Blomstedt G, Pyykkö I: Vestibular schwannoma surgery and headache. Acta Otolaryngol Suppl; 2000;543:23-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vestibular schwannoma surgery and headache.
  • The aim of the study was to evaluate aetiological factors for postoperative headache after vestibular schwannoma (VS) surgery with respect to asymmetric activation of vestibular reflexes.
  • [MeSH-minor] Adult. Aged. Anesthetics, Local / adverse effects. Dizziness / chemically induced. Female. Follow-Up Studies. Humans. Lidocaine / adverse effects. Male. Middle Aged. Reflex, Abnormal / physiology. Reflex, Vestibulo-Ocular / physiology. Serotonin Receptor Agonists / pharmacology. Serotonin Receptor Agonists / therapeutic use. Sumatriptan / pharmacology. Sumatriptan / therapeutic use. Trigeminal Nerve / drug effects. Trigeminal Nerve / physiopathology. Vertigo / chemically induced

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Headache.
  • Hazardous Substances Data Bank. Sumatriptan .
  • Hazardous Substances Data Bank. LIDOCAINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10908966.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] NORWAY
  • [Chemical-registry-number] 0 / Anesthetics, Local; 0 / Serotonin Receptor Agonists; 8R78F6L9VO / Sumatriptan; 98PI200987 / Lidocaine
  •  go-up   go-down


53. Abakumova OIu, Podobed OV, Borisova AA, Sidoruk KV, Aleksandrova SS, Omel'ianiuk NM, Pokrovskaia MV, Kondakova LI, Sokolov NN: [Antitumor activity of L-asparaginase from Yersinia pseudotuberculosis]. Biomed Khim; 2008 Nov-Dec;54(6):712-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxic activity of L-asparaginases from Yersinia pseudotuberculosis and from Erwinia carotovora were investigated in vitro using several tumor cells lines: Jurkat and Molt-4 (human T-lymphoblastic leukemia), MCF-7 (human breast adenocarcinoma), LnCap (human prostate carcinoma), NGUK1 (rat Gasser node neurinoma). E. coli L-asparaginase produced by "Medak" (Germany) was used as a reference.
  • The cell growth inhibition data indicate that Y. pseudotuberculosis L-asparaginase significantly inhibits growth of leukemic and solid tumor cells.
  • These results allow us to conclude that this L-asparaginase can be used for the development of new preparations for the therapy of different types of tumors.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Asparaginase / pharmacology. Yersinia pseudotuberculosis / enzymology
  • [MeSH-minor] Cell Line, Tumor. Drug Screening Assays, Antitumor. Humans. Pectobacterium carotovorum / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205431.001).
  • [ISSN] 2310-6972
  • [Journal-full-title] Biomedit︠s︡inskai︠a︡ khimii︠a︡
  • [ISO-abbreviation] Biomed Khim
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


54. Reusche E, Pilz P, Oberascher G, Lindner B, Egensperger R, Gloeckner K, Trinka E, Iglseder B: Subacute fatal aluminum encephalopathy after reconstructive otoneurosurgery: a case report. Hum Pathol; 2001 Oct;32(10):1136-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a 52-year-old woman who underwent otoneurosurgery to resect acoustic neurinoma.
  • These changes are characteristics of dialysis-associated encephalopathy (DAE), induced nowadays by long-term ingestion of Al-containing drugs (and with benign clinical courses).
  • [MeSH-minor] Aluminum Silicates / adverse effects. Aluminum Silicates / chemistry. Biocompatible Materials / adverse effects. Biocompatible Materials / chemistry. Bone Cements / adverse effects. Bone Cements / chemistry. Brain / drug effects. Brain / metabolism. Brain / pathology. Brain Chemistry. Fatal Outcome. Female. Glass Ionomer Cements / adverse effects. Humans. Middle Aged. Seizures / etiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • Hazardous Substances Data Bank. ALUMINUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company
  • (PMID = 11679949.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aluminum Silicates; 0 / Biocompatible Materials; 0 / Bone Cements; 0 / Glass Ionomer Cements; 0 / polymaleinate ionomer; CPD4NFA903 / Aluminum
  •  go-up   go-down


55. Scoles DR, Qin Y, Nguyen V, Gutmann DH, Pulst SM: HRS inhibits EGF receptor signaling in the RT4 rat schwannoma cell line. Biochem Biophys Res Commun; 2005 Sep 23;335(2):385-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HRS inhibits EGF receptor signaling in the RT4 rat schwannoma cell line.
  • Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) is required for trafficking of cell surface receptors to the lysosome.
  • Previously, we identified HRS as a protein that interacts with the neurofibromatosis 2 tumor suppressor schwannomin.
  • In the present study, we established modified RT4 schwannoma cell lines that inducibly express HRS and constitutively express epidermal growth factor receptor (EGFR) fused to the green fluorescent protein.
  • This study is the first to show that HRS can reduce the abundance of total and active EGFR and may reflect cell type-specific HRS function.
  • [MeSH-major] Neurilemmoma / metabolism. Phosphoproteins / physiology. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Dose-Response Relationship, Drug. Down-Regulation. Endosomal Sorting Complexes Required for Transport. Endosomes / metabolism. Green Fluorescent Proteins / metabolism. Immunoblotting. Microscopy, Fluorescence. Neurofibromin 2 / metabolism. Phosphorylation. Rats. Signal Transduction. Time Factors

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083858.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS01428-01A1; United States / NINDS NIH HHS / NS / NS35848
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endosomal Sorting Complexes Required for Transport; 0 / Neurofibromin 2; 0 / Phosphoproteins; 0 / hepatocyte growth factor-regulated tyrosine kinase substrate; 147336-22-9 / Green Fluorescent Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


56. Darrouzet V, Martel J, Enée V, Bébéar JP, Guérin J: Vestibular schwannoma surgery outcomes: our multidisciplinary experience in 400 cases over 17 years. Laryngoscope; 2004 Apr;114(4):681-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vestibular schwannoma surgery outcomes: our multidisciplinary experience in 400 cases over 17 years.
  • OBJECTIVES/HYPOTHESIS: The aim of the study was to evaluate the incidence of short- and intermediate-term postoperative complications after vestibular schwannoma surgery.
  • METHODS: In 400 patients who underwent surgical removal of vestibular schwannoma from 1984 to 2000,symptoms, preoperative evaluation, surgery, and postoperative complications were analyzed using standardized grading systems.
  • Tumor size according to Koos stage was stage 1 in 39 cases, stage 2 in 122 cases, stage 3 in 87 cases, and stage 4 in 152 cases.
  • At 1 year, House-Brackmann grade in 70.7% of patients was 1 to 2; in 24.3%, 3 to 4; and in 5%, 5 to 6.
  • Poor facial nerve outcome was correlated with tumor size, preoperative irradiation, and nerve dysfunction and was not correlated with the approach used.
  • CONCLUSION: Transpetrosal approaches (translabyrinthine, widened retrolabyrinthine) are safe for vestibular schwannoma removal, and rates of postoperative complications and sequelae are decreasing.
  • [MeSH-minor] Adolescent. Adult. Aged. Anticoagulants / therapeutic use. Cerebrospinal Fluid Otorrhea / epidemiology. Cerebrospinal Fluid Otorrhea / etiology. Child. Facial Paralysis / epidemiology. Facial Paralysis / etiology. Female. Heparin, Low-Molecular-Weight / therapeutic use. Humans. Male. Middle Aged. Outcome Assessment (Health Care). Patient Care Team. Pulmonary Embolism / drug therapy. Pulmonary Embolism / epidemiology. Pulmonary Embolism / etiology. Retrospective Studies. Vertigo / epidemiology. Vertigo / etiology. Wound Healing

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15064624.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Heparin, Low-Molecular-Weight
  •  go-up   go-down


57. Pollock BE: Vestibular schwannoma management: an evidence-based comparison of stereotactic radiosurgery and microsurgical resection. Prog Neurol Surg; 2008;21:222-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vestibular schwannoma management: an evidence-based comparison of stereotactic radiosurgery and microsurgical resection.
  • BACKGROUND: The best management of vestibular schwannoma (VS) patients is controversial.
  • METHODS: A comparison of surgical resection and stereotactic radiosurgery based on recent studies using evidence-based medicine standards.
  • CONCLUSION: The best quality of evidence (levels 2 and 3) show superior outcomes for VS patients having stereotactic radiosurgery compared to surgical resection allowing a grade B recommendation for this approach.
  • Unless long-term follow-up shows frequent tumor progression at currently used radiation doses, radiosurgery should be considered the best management strategy for the majority of VS patients.

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18810223.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 30
  •  go-up   go-down


58. Stieglitz LH, Samii A, Kaminsky J, Gharabaghi A, Samii M, Lüdemann WO: Nausea and dizziness after vestibular schwannoma surgery: a multivariate analysis of preoperative symptoms. Neurosurgery; 2005 Nov;57(5):887-90; discussion 887-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nausea and dizziness after vestibular schwannoma surgery: a multivariate analysis of preoperative symptoms.
  • OBJECTIVE: Nausea and dizziness are very discomforting for patients after vestibular schwannoma surgery and they impair recovery.
  • METHODS: To identify preoperative symptoms and conditions that increase the risk of development of nausea after vestibular schwannoma surgery, a multivariate analysis was performed.
  • One hundred fifteen patients with vestibular schwannoma had a microsurgical tumor removal in a standardized procedure in 2001 and 2002.
  • Eighteen patients were excluded from the study because of previous surgery (recurrent tumors, 7 patients) or bilateral tumor occurrence (neurofibromatosis, 11 patients).
  • Analysis was performed regarding postoperative amount of antiemetic medication, vomiting, and subjective feeling of the patient.
  • Tumor grading, body mass index, sex, previous complaints, examination at admission, and side of the tumor were taken in consideration.
  • Patients developing no significant postoperative complaints were all in the higher tumor grading group, Grades 3a, 4a, and 4b.
  • Patients with a positive stepping test preoperatively had a tendency to demand less antiemetic medication.
  • Women with small tumors are most likely to develop significant complaints after vestibular schwannoma surgery.
  • CONCLUSION: It is possible to identify patients with a higher risk of postoperative nausea and dizziness after vestibular schwannoma surgery.
  • This allows one to inform these patients preoperatively and to initiate an early postoperative drug therapy to ease their symptoms.


59. Pollack AG, Marymont MH, Kalapurakal JA, Kepka A, Sathiaseelan V, Chandler JP: Acute neurological complications following gamma knife surgery for vestibular schwannoma. Case report. J Neurosurg; 2005 Sep;103(3):546-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute neurological complications following gamma knife surgery for vestibular schwannoma. Case report.
  • The authors describe an acute facial and acoustic neuropathy following gamma knife surgery (GKS) for vestibular schwannoma (VS).
  • This 39-year-old woman presenting with tinnitus underwent GKS for a small right-sided intracanalicular VS, receiving a maximal dose of 26 Gy and a tumor margin dose of 13 Gy to the 50% isodose line.
  • Thirty-six hours following treatment she presented with nausea, vomiting, vertigo, diminished hearing, and a House-Brackmann Grade III facial palsy.
  • She was started on intravenous glucocorticosteroid agents, and over the course of 2 weeks her facial function returned to House-Brackmann Grade I.
  • A magnetic resonance (MR) image obtained at the time of initial deterioration demonstrated a significant decrease in tumor enhancement but no change in tumor size or peritumoral edema.
  • Subsequently, the patient experienced severe hemifacial spasms, which persisted for a period of 3 weeks and then progressed to a House-Brackmann Grade V facial palsy.
  • Results of MR imaging revealed transient enlargement (3 mm) of the tumor, which subsequently returned to its baseline size.
  • This change corresponded to the tumor volume increase from 270 to 336 mm3.
  • [MeSH-minor] Acute Disease. Adrenal Cortex Hormones / therapeutic use. Adult. Female. Humans. Magnetic Resonance Imaging. Tinnitus / etiology. Treatment Outcome

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16235688.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


60. Soffritti M, Belpoggi F, Degli Esposti D, Lambertini L, Tibaldi E, Rigano A: First experimental demonstration of the multipotential carcinogenic effects of aspartame administered in the feed to Sprague-Dawley rats. Environ Health Perspect; 2006 Mar;114(3):379-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The treatment lasted until natural death, at which time all deceased animals underwent complete necropsy.
  • The results of the study show for the first time that APM, in our experimental conditions, causes a) an increased incidence of malignant-tumor-bearing animals with a positive significant trend in males (p < or = 0.05) and in females (p < or = 0.01), in particular those females treated at 50,000 ppm (p < or = 0.01);.
  • c) a statistically significant increased incidence, with a positive significant trend (p < or = 0.01), of transitional cell carcinomas of the renal pelvis and ureter and their precursors (dysplasias) in females treated at 100,000 (p < or = 0.01), 50,000 (p < or = 0.01), 10,000 (p < or = 0.01), 2,000 (p < or = 0.05), or 400 ppm (p < or = 0.05); and d) an increased incidence of malignant schwannomas of peripheral nerves with a positive trend (p < or = 0.05) in males.
  • The results of this mega-experiment indicate that APM is a multipotential carcinogenic agent, even at a daily dose of 20 mg/kg body weight, much less than the current acceptable daily intake.
  • [MeSH-major] Aspartame / toxicity. Sweetening Agents / toxicity
  • [MeSH-minor] Animals. Carcinoma / chemically induced. Carcinoma / pathology. Female. Kidney Neoplasms / chemically induced. Kidney Neoplasms / pathology. Leukemia / chemically induced. Lymphoma / chemically induced. Male. Rats. Rats, Sprague-Dawley. Ureteral Neoplasms / chemically induced

  • Hazardous Substances Data Bank. Aspartame .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 2002 Dec;982:26-45 [12562627.001]
  • [Cites] Toxicol Pathol. 1996 Sep-Oct;24(5):573-9 [8923678.001]
  • [Cites] Ann N Y Acad Sci. 2002 Dec;982:87-105 [12562630.001]
  • [Cites] J Toxicol Environ Health. 1976 Nov;2(2):441-51 [827618.001]
  • [Cites] J Natl Cancer Inst. 1979 Apr;62(4):957-74 [285297.001]
  • [Cites] Toxicol Lett. 1981 Mar;7(6):433-7 [7245229.001]
  • [Cites] Toxicology. 1981;21(2):91-4 [7281205.001]
  • [Cites] Biometrics. 1988 Jun;44(2):417-31 [3390507.001]
  • [Cites] Fundam Appl Toxicol. 1989 May;12(4):731-7 [2744275.001]
  • [Cites] Environ Health Perspect. 1989 Jul;82:109-24 [2792037.001]
  • [Cites] Toxicol Ind Health. 1989 Oct;5(5):699-730 [2815102.001]
  • [Cites] Jpn J Cancer Res. 1989 Sep;80(9):795-807 [2513295.001]
  • [Cites] IARC Sci Publ. 1993;(122 Pt I-4):1-27 [8270318.001]
  • [Cites] Ann N Y Acad Sci. 2002 Dec;982:46-69 [12562628.001]
  • [Cites] Environ Health Perspect. 1995 Sep;103 Suppl 6:173-5 [8549469.001]
  • [Cites] Toxicol Ind Health. 1995 Mar-Apr;11(2):119-49 [7491630.001]
  • [Cites] World Rev Nutr Diet. 1999;85:201-11 [10647352.001]
  • [Cites] Ann N Y Acad Sci. 1999;895:34-55 [10676408.001]
  • [Cites] Ann N Y Acad Sci. 1999;895:56-79 [10676409.001]
  • [Cites] Food Chem Toxicol. 2000 Jan;38(1):75-7 [10685017.001]
  • [Cites] Food Chem Toxicol. 2000 Apr;38(4):335-8 [10722887.001]
  • [CommentIn] Environ Health Perspect. 2007 Jan;115(1):A16-7; author reply A17 [17366802.001]
  • [CommentIn] Environ Health Perspect. 2006 Sep;114(9):A516; author reply A516-7 [16966071.001]
  • [CommentIn] Environ Health Perspect. 2006 Mar;114(3):A176 [16528837.001]
  • (PMID = 16507461.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sweetening Agents; Z0H242BBR1 / Aspartame
  • [Other-IDs] NLM/ PMC1392232
  •  go-up   go-down


61. Sekiya T, Yagihashi A, Asano K, Suzuki S: Nimodipine ameliorates trauma-induced cochlear neuronal death. Neurol Res; 2002 Dec;24(8):775-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Excessive entry of Ca2+ into injured cochlear neurons activates various Ca(2+)-activated enzymes and subsequent spiral ganglion cell death.
  • Therefore, preventing intracellular calcium overload by using Ca2+ channel antagonists may become an important countermeasure to spiral ganglion cell death.
  • We experimentally investigated whether an L-type Ca2+ channel blocker (nimodipine) can rescue traumatized cochlear neurons from degeneration.
  • The results of the present study indicate that nimodipine may become an intra- and post-operative important adjunct to raise the rate of hearing preservation in vestibular schwannoma excision or other cerebellopontine angle surgical interventions.
  • [MeSH-major] Calcium Channel Blockers / pharmacology. Cochlear Nerve / drug effects. Cochlear Nerve / injuries. Nerve Degeneration / drug therapy. Nimodipine / pharmacology. Spiral Ganglion / physiopathology. Vestibulocochlear Nerve Diseases / drug therapy
  • [MeSH-minor] Animals. Calcium / metabolism. Calcium Signaling / drug effects. Calcium Signaling / physiology. Cell Death / drug effects. Cell Death / physiology. Disease Models, Animal. Immunohistochemistry. Male. Nerve Crush. Neuroma, Acoustic / surgery. Neurons, Afferent / drug effects. Neurons, Afferent / metabolism. Neurons, Afferent / pathology. Neurosurgical Procedures / adverse effects. Rats. Rats, Sprague-Dawley. Stress, Mechanical

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12500700.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 57WA9QZ5WH / Nimodipine; SY7Q814VUP / Calcium
  •  go-up   go-down


62. Cardoso I, Almeida MR, Ferreira N, Arsequell G, Valencia G, Saraiva MJ: Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design. Biochem J; 2007 Nov 15;408(1):131-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design.
  • Plasmids carrying wild-type TTR, V30M or L55P cDNA were transfected into a rat Schwannoma cell line and TTR aggregates were investigated in the medium using a dot-blot filter assay followed by immunodetection.
  • Results showed that, in 24 h, TTR L55P forms aggregates in the medium, whereas, up to 72 h, wild-type TTR and V30M do not.
  • Among these drugs, 2-[(3,5-dichlorophenyl) amino] benzoic acid and tri-iodophenol stabilized TTR from heterozygotic carriers of V30M in the same ex vivo conditions as those used previously for iododiflunisal.
  • The novel cellular-based test herein proposed for TTR fibrillogenesis inhibitor screens avoids not only lengthy and cumbersome large-scale protein isolation steps but also artefacts associated with most current in vitro first-line screening methods, such as those associated with acidic conditions and the absence of serum proteins.
  • [MeSH-major] Drug Design. Prealbumin / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Gene Expression. Humans. Mass Spectrometry. Microscopy, Electron, Transmission. Mutation / genetics. Protein Binding / drug effects. Protein Folding. Rats

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Exp Ther. 2006 Jun;317(3):1143-9 [16495207.001]
  • [Cites] APMIS. 1997 Aug;105(8):603-8 [9298097.001]
  • [Cites] Bioorg Med Chem. 1998 Aug;6(8):1389-401 [9784876.001]
  • [Cites] Bioorg Med Chem Lett. 1999 Jan 4;9(1):1-6 [9990446.001]
  • [Cites] Bioorg Med Chem. 1999 Jul;7(7):1339-47 [10465408.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] J Biol Chem. 2004 Dec 17;279(51):53483-90 [15469931.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14545-50 [16195386.001]
  • [Cites] J Neural Transm (Vienna). 2006 Feb;113(2):125-35 [15959846.001]
  • [Cites] J Lipid Res. 2000 Jan;41(1):58-65 [10627502.001]
  • [Cites] Nat Struct Biol. 2000 Apr;7(4):312-21 [10742177.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):1993-2000 [11733349.001]
  • [Cites] J Med Chem. 2002 Jan 17;45(2):321-32 [11784137.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1935-48 [12414539.001]
  • [Cites] FASEB J. 2003 May;17(8):803-9 [12724338.001]
  • [Cites] Angew Chem Int Ed Engl. 2003 Jun 23;42(24):2758-61 [12820260.001]
  • [Cites] J Am Chem Soc. 2003 Nov 5;125(44):13404-14 [14583036.001]
  • [Cites] J Med Chem. 2004 Jan 15;47(2):355-74 [14711308.001]
  • [Cites] J Mol Neurosci. 2004;23(1-2):35-40 [15126690.001]
  • [Cites] Biochem J. 2004 Jul 15;381(Pt 2):351-6 [15080795.001]
  • [Cites] Biochemistry. 1991 Mar 5;30(9):2415-21 [1848097.001]
  • [Cites] EMBO J. 1993 Feb;12(2):735-41 [8382610.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5011-5 [8506346.001]
  • [Cites] J Biol Chem. 1995 Jun 16;270(24):14786-92 [7782344.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15051-6 [8986762.001]
  • [Cites] J Biol Chem. 1997 Apr 25;272(17):11006-10 [9110991.001]
  • [Cites] Endocrine. 1997 Jun;6(3):309-15 [9368688.001]
  • (PMID = 17683281.001).
  • [ISSN] 1470-8728
  • [Journal-full-title] The Biochemical journal
  • [ISO-abbreviation] Biochem. J.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Prealbumin
  • [Other-IDs] NLM/ PMC2049069
  •  go-up   go-down


63. Seeley SL, Bosco EE, Kramer E, Parysek LM, Knudsen ES: Distinct roles for RB loss on cell cycle control, cisplatin response, and immortalization in Schwann cells. Cancer Lett; 2007 Jan 8;245(1-2):205-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct roles for RB loss on cell cycle control, cisplatin response, and immortalization in Schwann cells.
  • Schwann cells play a critical role in peripheral nerve function.
  • Regulated proliferation of Schwann cells is an important facet of the response to nerve injury; however, aberrant proliferation can give rise to Schwann cell tumors such as malignant peripheral nerve sheath tumors (MPNST).
  • These tumors exhibit a range of genetic lesions that include loss of the retinoblastoma tumor suppressor (RB) pathway.
  • Here, the specific action of RB loss on Schwann cell proliferation and response to therapeutic intervention was explored.
  • In primary mouse Schwann cells, conditional RB loss led to increased levels of critical cell cycle regulatory gene products, yet provided only a modest influence on proliferation.
  • However, RB-deficient Schwann cells efficiently bypassed the cell cycle inhibitory response to the chemotherapeutic agent cisplatin, which is used in the treatment of MPNST and other glial tumors.
  • Surprisingly, RB loss did not facilitate Schwann cell immortalization; and RB-deficient cells actually were less prone to immortalization than cells containing RB.
  • Furthermore, RB-deficient cells that ultimately re-entered the cell cycle had lost both Schwann cell morphology and markers.
  • Since, RB loss is likely a late event in Schwann cell tumor progression, the action of acute RB loss in immortalized Schwann cells was investigated.
  • Thus, the loss of RB in both primary and immortal Schwann cells disrupted the response to anti-mitogenic signals and has implications for therapeutic intervention.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16574317.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA117846; United States / NCI NIH HHS / CA / CA104213; United States / NCI NIH HHS / CA / CA106471; United States / NINDS NIH HHS / NS / NS35313
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Proliferating Cell Nuclear Antigen; 0 / Receptors, Nerve Growth Factor; 0 / Retinoblastoma Protein; 0 / TNFRSF16 protein, mouse; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


64. Levo H, Blomstedt G, Pyykkö I: Is hearing preservation useful in vestibular schwannoma surgery? Ann Otol Rhinol Laryngol; 2002 May;111(5 Pt 1):392-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is hearing preservation useful in vestibular schwannoma surgery?
  • The goal of our study was to examine the usefulness of preserved hearing after unilateral vestibular schwannoma removal.
  • [MeSH-minor] Audiometry. Data Interpretation, Statistical. Follow-Up Studies. Hearing Disorders / diagnosis. Hearing Disorders / prevention & control. Humans. Hypnotics and Sedatives / therapeutic use. Logistic Models. Middle Aged. Monitoring, Physiologic. Persons With Hearing Impairments. Risk Factors. Sleep Initiation and Maintenance Disorders / drug therapy. Sleep Initiation and Maintenance Disorders / etiology. Surveys and Questionnaires. Time Factors. Tinnitus / etiology

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12018322.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypnotics and Sedatives
  •  go-up   go-down


65. Susen K, Blöchl A: Low concentrations of aggregated beta-amyloid induce neurite formation via the neurotrophin receptor p75. J Mol Med (Berl); 2005 Sep;83(9):720-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined this signaling process in different cell lines which express p75 either naturally (Schwannoma RN22 cells) or which are stably transfected with wild-type p75 (MDCKwt and PCNA cells) or with a truncated form of p75 comprising only extracellular and transmembrane domains (MDCKtm cells).
  • While Abeta in higher concentrations (10-100 microM) is known to cause apoptosis via p75, our experiments focused on the effects of low concentrations of Abeta (25 nM) which may occur in early stages of Alzheimer disease.
  • Application of Abeta caused tyrosine phosphorylation of wild-type p75 and induced the Ras-ERK pathway as has been reported for nerve growth factor (NGF).
  • But while NGF distinctly promoted neurite branching and elongation, Abeta was less effective in neurite elongation and counts of small processes and of growth cones remained clearly elevated after 24-h stimulation; these peculiarities might be linked to aberrant neuronal connections reported for an animal model of Alzheimer disease.
  • [MeSH-major] Amyloid beta-Peptides / pharmacology. Neurites / metabolism. Receptor, Nerve Growth Factor / metabolism. Signal Transduction / drug effects
  • [MeSH-minor] Alzheimer Disease / metabolism. Animals. Apoptosis / drug effects. Carbazoles / pharmacology. Cell Line, Tumor. Dose-Response Relationship, Drug. Enzyme Inhibitors / pharmacology. Humans. Indole Alkaloids. Protein Kinases / metabolism. Protein Structure, Tertiary. Rats. Transfection


66. Schaller B, Baumann A: Headache after removal of vestibular schwannoma via the retrosigmoid approach: a long-term follow-up-study. Otolaryngol Head Neck Surg; 2003 Mar;128(3):387-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Headache after removal of vestibular schwannoma via the retrosigmoid approach: a long-term follow-up-study.
  • OBJECTIVE: Our goal was to study the occurrence and source of origin of postcraniotomy headache syndrome after removal of vestibular schwannoma via the retrosigmoid approach.
  • METHODS: A retrospective chart analysis was conducted of all patients with headache at 3 months after removal of vestibular schwannoma from January 1981 through March 1997 and with a minimum of 24 months of follow-up.
  • RESULTS: Of the patients who underwent retrosigmoid craniotomy for removal of vestibular schwannomas, 52 of 155 patients (34%) reported having severe headache of requiring medication every day and/or feeling incapacitated 3 months after surgery.
  • Headache was more prevalent in those who had the bone flap replaced (94% versus 27%), if there was duraplastic or direct dura closure (0% versus 100%).
  • CONCLUSION: The origin of postoperative headaches after retrosigmoid vestibular schwannoma resections is not yet fully understood.

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Headache.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12646842.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrin Tissue Adhesive; 0 / Tissue Adhesives
  •  go-up   go-down


67. Kinfe TM, Capelle HH, Krauss JK: Impact of surgical treatment on tremor due to posterior fossa tumors. J Neurosurg; 2008 Apr;108(4):692-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients who had been treated with neuroleptic medication or had a family history of movement disorders were excluded.
  • Five patients underwent total or subtotal tumor resection, and 1 patient underwent stereotactic biopsy only.
  • The histological diagnosis was epidermoid tumor in 2 patients, metastasis in 2 others, and vestibular schwannoma and low-grade glioma in 1 each.
  • In both of these patients the tumor (low-grade glioma in 1, metastasis in the other) involved the dentate nucleus directly.
  • The prognosis appears to be favorable in those patients with compression of these substrates, whereas primary invasion by tumor has a poor prognosis.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Infratentorial Neoplasms / complications. Tremor / etiology. Tremor / surgery

  • Genetic Alliance. consumer health - Tremor.
  • MedlinePlus Health Information. consumer health - Tremor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18377248.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Lee HK, Seo IA, Suh DJ, Lee HJ, Park HT: A novel mechanism of methylglyoxal cytotoxicity in neuroglial cells. J Neurochem; 2009 Jan;108(1):273-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, MGO suppresses cell viability through the induction of apoptosis in vitro.
  • In this study, we have, for the first time, demonstrated the effect of MGO on the gp130 cytokine-induced signal transducer and activator of transcription 3 (STAT3) responses in RT4 schwannoma, PC12 pheochromocytoma and U87MG glioma cells.
  • At dose that very mildly affects cell viability, MGO rapidly induces endocytotic degradation of gp130, which involves the di-leucine internalization motif in the cytoplasmic domain of gp130, without affecting other growth factor receptors.
  • Our data indicate that MGO affects cell viability via desensitization of gp130/STAT3 signaling, which is the key signaling pathway for cell survival, and thereby promotes cytotoxicity.
  • [MeSH-major] Neuroglia / drug effects. Pyruvaldehyde / pharmacology
  • [MeSH-minor] Animals. Antineoplastic Agents, Phytogenic / pharmacology. Cell Survival. Cells, Cultured. Cytokine Receptor gp130 / metabolism. Dose-Response Relationship, Drug. Etoposide / pharmacology. Flow Cytometry. Hydrogen Peroxide / pharmacology. Interleukin-6 / pharmacology. Protein Binding / drug effects. Protein Binding / physiology. Protein Processing, Post-Translational / drug effects. Protein Transport / drug effects. Rats. Rats, Sprague-Dawley. STAT3 Transcription Factor / metabolism. Sciatic Nerve / cytology. Signal Transduction / drug effects. Tetrazolium Salts. Thiazoles. Time Factors. Transfection / methods

  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • Hazardous Substances Data Bank. METHYL GLYOXAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19012752.001).
  • [ISSN] 1471-4159
  • [Journal-full-title] Journal of neurochemistry
  • [ISO-abbreviation] J. Neurochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Interleukin-6; 0 / STAT3 Transcription Factor; 0 / Stat3 protein, rat; 0 / Tetrazolium Salts; 0 / Thiazoles; 133483-10-0 / Cytokine Receptor gp130; 298-93-1 / thiazolyl blue; 6PLQ3CP4P3 / Etoposide; 722KLD7415 / Pyruvaldehyde; BBX060AN9V / Hydrogen Peroxide
  •  go-up   go-down


69. Scoles DR, Nguyen VD, Qin Y, Sun CX, Morrison H, Gutmann DH, Pulst SM: Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling. Hum Mol Genet; 2002 Dec 1;11(25):3179-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling.
  • Mutations in the neurofibromatosis 2 (NF2) gene with the resultant loss of expression of the NF2 tumor suppressor schwannomin are one of the most common causes of benign human brain tumors, including schwannomas and meningiomas.
  • We now show that both schwannomin and HRS inhibit Stat3 activation and that schwannomin suppresses Stat3 activation mediated by IGF-I treatment in the human schwannoma cell line STS26T.
  • We also find that schwannomin inhibits Stat3 and Stat5 phosphorylation in the rat schwannoma cell line RT4.
  • [MeSH-major] DNA-Binding Proteins / physiology. Milk Proteins. Neurofibromatosis 2 / genetics. Neurofibromin 2 / physiology. Phosphoproteins / physiology. Signal Transduction / physiology. Trans-Activators / physiology
  • [MeSH-minor] Acute-Phase Proteins / antagonists & inhibitors. Acute-Phase Proteins / physiology. Amino Acid Sequence. Animals. Cell Division / drug effects. Endosomal Sorting Complexes Required for Transport. Humans. Insulin-Like Growth Factor I / pharmacology. Molecular Sequence Data. Neurilemmoma / genetics. Neurilemmoma / metabolism. Neurilemmoma / pathology. Peptides / chemistry. Peptides / immunology. Phosphorylation. Rats. STAT3 Transcription Factor. STAT5 Transcription Factor. Soft Tissue Neoplasms / genetics. Soft Tissue Neoplasms / metabolism. Soft Tissue Neoplasms / pathology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12444102.001).
  • [ISSN] 0964-6906
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1S10-RR13717; United States / NINDS NIH HHS / NS / NS01428-01A1; United States / NINDS NIH HHS / NS / NS10524-02; United States / NINDS NIH HHS / NS / NS35848
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / DNA-Binding Proteins; 0 / Endosomal Sorting Complexes Required for Transport; 0 / Milk Proteins; 0 / Neurofibromin 2; 0 / Peptides; 0 / Phosphoproteins; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / STAT5 Transcription Factor; 0 / Stat3 protein, rat; 0 / Trans-Activators; 0 / hepatocyte growth factor-regulated tyrosine kinase substrate; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


70. Chung WY, Liu KD, Shiau CY, Wu HM, Wang LW, Guo WY, Ho DM, Pan DH: Gamma knife surgery for vestibular schwannoma: 10-year experience of 195 cases. J Neurosurg; 2005 Jan;102 Suppl:87-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife surgery for vestibular schwannoma: 10-year experience of 195 cases.
  • OBJECT: The authors conducted a study to determine the optimal radiation dose for vestibular schwannoma (VS) and to examine the histopathology in cases of treatment failure for better understanding of the effects of irradiation.
  • Seventy-two patients (37%) had undergone partial or total excision of their tumor prior to gamma knife surgery (GKS).
  • The mean tumor volume was 4.1 cm3 (range 0.04-23.1 cm3).
  • Multiisocenter dose planning placed a prescription dose of 11 to 18.2 Gy on the 50 to 94% isodose located at the tumor margin.
  • At the latest MR imaging assessment decreased or stable tumor volume was demonstrated in 93.6% of the patients.
  • Uncontrolled tumor swelling was noted in five patients at 3.5, 17, 24, 33, and 62 months after GKS, respectively.
  • Histopathological examination of specimens in three cases (one at 62 months after GKS) revealed a long-lasting radiation effect on vessels inside the tumor.
  • A margin 12-Gy dose with homogeneous distribution is effective in preventing tumor progression, while posing no serious threat to normal cranial nerve function.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anti-Inflammatory Agents / therapeutic use. Child. Facial Paralysis / diagnosis. Facial Paralysis / drug therapy. Facial Paralysis / etiology. Female. Follow-Up Studies. Hearing Disorders / diagnosis. Hearing Disorders / etiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radiation Dosage. Severity of Illness Index. Tinnitus / etiology. Trigeminal Neuralgia / epidemiology. Trigeminal Neuralgia / etiology. Trigeminal Neuralgia / physiopathology

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662787.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents
  •  go-up   go-down


71. Youssef AS, Downes AE: Intraoperative neurophysiological monitoring in vestibular schwannoma surgery: advances and clinical implications. Neurosurg Focus; 2009 Oct;27(4):E9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative neurophysiological monitoring in vestibular schwannoma surgery: advances and clinical implications.
  • OBJECT: Intraoperative neurophysiological monitoring has become an integral part of vestibular schwannoma surgery.
  • The aim of this article was to review the different techniques of intraoperative neurophysiological monitoring in vestibular schwannoma surgery, identify the clinical impact of certain pathognomonic patterns on postoperative outcomes of facial nerve function and hearing preservation, and highlight the role of postoperative medications in improving delayed cranial nerve dysfunction in the different reported series.
  • METHODS: The authors performed a review of the literature regarding intraoperative monitoring in acoustic/vestibular schwannoma surgery.
  • Recently, perioperative administration of intravenous hydroxyethyl starch and nimodipine as vasoactive and neuroprotective agents was shown to improve vestibular schwannoma functional outcome in few reported studies.

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19795957.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydroxyethyl Starch Derivatives; 57WA9QZ5WH / Nimodipine
  • [Number-of-references] 35
  •  go-up   go-down


72. Gharabaghi A, Koerbel A, Samii A, Kaminsky J, von Goesseln H, Tatagiba M, Samii M: The impact of hypotension due to the trigeminocardiac reflex on auditory function in vestibular schwannoma surgery. J Neurosurg; 2006 Mar;104(3):369-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of hypotension due to the trigeminocardiac reflex on auditory function in vestibular schwannoma surgery.
  • The authors studied the impact of this reflex on postoperative auditory function in patients undergoing vestibular schwannoma (VS) surgery.
  • The evaluation included sex, age, pre- and postoperative auditory function, preoperative mean arterial blood pressure, preoperative medical diseases or medication (for example, antiarrhythmia drugs), tumor size and localization, and the intraoperative occurrence of the TCR.


73. Alderson NL, Hama H: Fatty acid 2-hydroxylase regulates cAMP-induced cell cycle exit in D6P2T schwannoma cells. J Lipid Res; 2009 Jun;50(6):1203-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatty acid 2-hydroxylase regulates cAMP-induced cell cycle exit in D6P2T schwannoma cells.
  • In many cell types, a fraction of sphingolipids contain 2-hydroxy fatty acids, produced by fatty acid 2-hydroxylase (FA2H), as the N-acyl chain of ceramide [hydroxyl fatty acid (hFA)-sphingolipids].
  • While hFA-sphingolipids are thought to enhance the physical stability of specialized membranes produced by these cells, physiological significance of hFA-sphingolipids in many other cell types is unknown.
  • In this study, we report novel roles for FA2H and hFA-sphingolipids in the regulation of the cell cycle.
  • Treatment of D6P2T Schwannoma cells with dibutyryl-cAMP (db-cAMP) induced exit from the cell cycle with concomitant upregulation of FA2H.
  • Under these conditions, db-cAMP no longer induced cell cycle exit, and cells continued to grow and divide.
  • These results provide evidence that FA2H is a negative regulator of the cell cycle and facilitates db-cAMP-induced cell cycle exit in D6P2T cells.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1989 Jul 15;264(20):12097-105 [2745431.001]
  • [Cites] Lipids. 1986 Feb;21(2):107-11 [3959770.001]
  • [Cites] Cancer Res. 1992 Jan 15;52(2):416-21 [1728413.001]
  • [Cites] Eur J Biochem. 1992 Jan 15;203(1-2):107-13 [1730216.001]
  • [Cites] J Biol Chem. 1992 Jan 25;267(3):1746-51 [1730716.001]
  • [Cites] J Lipid Res. 1992 Mar;33(3):301-13 [1569381.001]
  • [Cites] Glycoconj J. 1989;6(3):303-18 [2535491.001]
  • [Cites] Adv Lipid Res. 1993;26:353-72 [8379458.001]
  • [Cites] J Neurosci Res. 1997 Nov 1;50(3):373-82 [9364322.001]
  • [Cites] Anal Biochem. 1999 May 15;270(1):41-9 [10328763.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):48562-8 [15337768.001]
  • [Cites] Biochem J. 2005 May 15;388(Pt 1):245-54 [15658937.001]
  • [Cites] J Lipid Res. 2005 Jul;46(7):1569-75 [15863841.001]
  • [Cites] Biochimie. 2005 Dec;87(12):1121-6 [15953673.001]
  • [Cites] Glia. 2006 Jan 15;53(2):147-57 [16206162.001]
  • [Cites] Cancer Sci. 2006 Dec;97(12):1321-6 [16995873.001]
  • [Cites] J Lipid Res. 2006 Dec;47(12):2772-80 [16998236.001]
  • [Cites] J Biol Chem. 2007 May 4;282(18):13211-9 [17355976.001]
  • [Cites] J Lipid Res. 2008 Jan;49(1):153-61 [17901466.001]
  • [Cites] J Neurochem. 1987 Dec;49(6):1902-11 [2824698.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Feb;9(2):139-50 [18216770.001]
  • [Cites] Dev Cell. 2008 Feb;14(2):159-69 [18267085.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):253-67 [18354415.001]
  • [Cites] J Lipid Res. 2008 Nov;49(11):2356-64 [18541923.001]
  • [Cites] J Neurosci. 2000 Jun 15;20(12):4627-34 [10844032.001]
  • [Cites] J Neurochem. 2001 Feb;76(3):778-88 [11158249.001]
  • [Cites] J Neurosci Res. 2002 Aug 15;69(4):497-508 [12210843.001]
  • [Cites] Curr Opin Hematol. 2003 Jan;10(1):16-24 [12483107.001]
  • [Cites] Pharmacol Res. 2003 May;47(5):383-92 [12676512.001]
  • [Cites] Semin Cell Dev Biol. 2004 Aug;15(4):409-16 [15207831.001]
  • [Cites] EMBO Rep. 2004 Aug;5(8):777-82 [15289826.001]
  • [Cites] J Biol Chem. 1971 Mar 10;246(5):1192-200 [5545063.001]
  • [Cites] Lipids. 1975 Jan;10(1):17-9 [1123973.001]
  • [Cites] J Lipid Res. 1975 May;16(3):189-94 [1168686.001]
  • [Cites] J Lipid Res. 1982 Feb;23(2):327-34 [7077147.001]
  • [Cites] J Biol Chem. 1984 Apr 10;259(7):4672-80 [6707026.001]
  • [Cites] Cancer Res. 1986 Mar;46(3):1403-7 [3002616.001]
  • [Cites] Mol Cell Biol. 1990 May;10(5):2176-81 [2183021.001]
  • (PMID = 19171550.001).
  • [ISSN] 0022-2275
  • [Journal-full-title] Journal of lipid research
  • [ISO-abbreviation] J. Lipid Res.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS-060807; United States / NCRR NIH HHS / RR / RR-17677
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ceramides; 0 / Fatty Acids; 0 / RNA, Small Interfering; 0 / Sphingolipids; 63X7MBT2LQ / Bucladesine; EC 1.- / Mixed Function Oxygenases; EC 1.- / fatty acid alpha-hydroxylase
  • [Other-IDs] NLM/ PMC2681402
  •  go-up   go-down


74. Schoemaker MJ, Swerdlow AJ, Auvinen A, Christensen HC, Feychting M, Johansen C, Klaeboe L, Lönn S, Salminen T, Tynes T: Medical history, cigarette smoking and risk of acoustic neuroma: an international case-control study. Int J Cancer; 2007 Jan 1;120(1):103-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acoustic neuroma (vestibular schwannoma) is a benign tumor of the vestibulocochlear nerve.
  • Its recorded incidence is increasing but risk factors for this tumor have scarcely been investigated.
  • Tumor risk was analyzed in relation to medical history and cigarette smoking.
  • Risk was not associated with a history of allergic disease, past head injury, past diagnosis of a neoplasm or birth characteristics, but was significantly raised for past diagnosis of epilepsy (OR = 2.5, 95% CI: 1.3-4.9).
  • Tumor risk was significantly reduced in subjects who had ever regularly smoked cigarettes (OR = 0.7, 95% CI: 0.6-0.9), but the reduction applied only to current smokers (OR = 0.5, 95% CI: 0.4-0.6), not ex-smokers (OR = 1.0, 95% CI: 0.8-1.3).
  • The reduced risk of acoustic neuroma in smokers and raised risk in parous women might relate to sex hormone levels, or smoking might suppress tumor growth, but effects of parity and smoking on timing of diagnosis of the tumor are also a potential explanation.
  • The raised risk in relation to past diagnosis of epilepsy might be a surveillance artefact or imply that epilepsy and/or antiepileptic medication use predispose to acoustic neuroma.
  • [MeSH-minor] Adolescent. Adult. Aged. Asthma / complications. Case-Control Studies. Eczema / complications. Epilepsy / complications. Epilepsy / drug therapy. Female. Humans. Male. Medical History Taking. Middle Aged. Risk Factors


75. Miettinen M: From morphological to molecular diagnosis of soft tissue tumors. Adv Exp Med Biol; 2006;587:99-113
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many sarcomas are known to have such fusions, and the demonstration of the fusion transcripts in tumor tissue is of great value in specific diagnosis of synovial sarcoma (SYT-SSX), Ewing sarcoma (EWS-Fli1), clear cell sarcoma (EWS-ATF1), myxoid liposarcoma (FUS-CHOP), and other sarcomas.
  • These translocations are believed to be disease-specific and pathogenetic forces, despite occasional observations to the contrary.
  • Demonstration of SYT-SSX and EWS-ATF1 fusion assists in the diagnosis of synovial and clear cell sarcomas in unusual locations, such as the gastrointestinal tract, where these tumors occur with low frequency.
  • In two exceptional instances, the same translocation and gene fusion occurs in two unrelated diseases: ETV6-NTRK fusion in infantile fibrosarcoma and secretory carcinoma of the breast, and ALK-TPM3 fusion in inflammatory myofibroblastic tumor and large cell anaplastic lymphoma.
  • Thus, the target cell of the genetic change is an important factor to define the resulting disease.
  • Mutation type influences therapy responsiveness, but fortunately very few GISTs carry primarily Imatinib-resistant mutations.
  • Secondary drug resistance acquired during Imatinib treatment based on new, Imatinib-resistant mutations is a major problem limiting treatment success.
  • Loss of NF2 tumor suppressor gene in a biallelic fashion is believed to be central in the pathogenesis of neurofibromatosis 2 (NF2) associated and sporadic schwannomas and meningiomas.
  • Schwannoma types may differ in their pathogenesis: gastrointestinal schwannomas lack NF2 changes suggesting a different pathogenesis.
  • Specific viral sequences of human herpesvirus 8 (HHV8) are diagnostic markers for Kaposi sarcoma (KS), and are absent in angiosarcoma.

  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17163160.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 70
  •  go-up   go-down


76. Uematsu H, Maeda M, Sadato N, Matsuda T, Ishimori Y, Koshimoto Y, Yamada H, Kimura H, Kawamura Y, Matsuda T, Hayashi N, Yonekura Y, Ishii Y: Vascular permeability: quantitative measurement with double-echo dynamic MR imaging--theory and clinical application. Radiology; 2000 Mar;214(3):912-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vascularity was evaluated on the basis of the T2*-shortening effect due to the intravascular fraction of the contrast agent and permeability on the basis of the T1-shortening effect due to the extravascular fraction.
  • Meningioma was characterized on the basis of higher vascularity and neurinoma on the basis of higher permeability.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10715068.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


77. Mack JT, Townsend DM, Beljanski V, Tew KD: The ABCA2 transporter: intracellular roles in trafficking and metabolism of LDL-derived cholesterol and sterol-related compounds. Curr Drug Metab; 2007 Jan;8(1):47-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ATP-binding cassette (ABC) transporters comprise a family of critical membrane bound proteins functioning in the translocation of molecules across cellular membranes.
  • Substrates for transport include lipids, cholesterol and pharmacological agents.
  • Mutations in ABC transporter genes cause a variety of human pathologies and elicit drug resistance phenotypes in cancer cells.
  • ABCA2, the second member the A subfamily to be identified, was highly expressed in ovarian carcinoma cells resistant to the anti-cancer agent, estramustine, and more recently, in human vestibular schwannomas.
  • This transporter, along with other proteins that have a high degree of homology to ABCA2, including ABCA1 and ABCA7, are up-regulated in human macrophages during cholesterol import.
  • A single nucleotide polymorphism in exon 14 of the ABCA2 gene was shown to be linked to early onset Alzheimer disease (AD) in humans, supporting an earlier study showing ABCA2 expression influences levels of APP and beta-amyloid peptide, the primary component of senile plaques.
  • [MeSH-minor] Alzheimer Disease / etiology. Amino Acid Sequence. Cholesterol, LDL / metabolism. Drug Resistance, Multiple. Molecular Sequence Data. Mutation. Neoplasms / etiology. Protein Transport. Sterols / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17266523.001).
  • [ISSN] 1389-2002
  • [Journal-full-title] Current drug metabolism
  • [ISO-abbreviation] Curr. Drug Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / ABCA2 protein, human; 0 / ATP-Binding Cassette Transporters; 0 / Cholesterol, LDL; 0 / Sterols
  • [Number-of-references] 119
  •  go-up   go-down


78. Tsuchigauchi T, Takahashi T, Ohnishi T, Ogawa H, Bando Y, Uehara H, Takizawa T, Kaneda S, Nakai T, Shiota H, Izumi K: Low susceptibility to N-ethyl-N-nitrosourea-induced transplacental carcinogenesis in Long-Evans Cinnamon (LEC) rats. J Med Invest; 2009 Aug;56(3-4):93-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Long-Evans Cinnamon (LEC) rat, an animal model of Wilson's disease, is resistant to a variety of chemical carcinogenesis except liver and colon.
  • Cerebral/spinal gliomas and trigeminal/spinal nerve schwannomas developed in both LEA and F344 rats at 30 weeks of age, but no nervous system tumors developed in LEC rats, the difference being statistically significant.
  • [MeSH-minor] Animals. Base Sequence. Female. Liver / drug effects. Liver / metabolism. Lung Neoplasms / chemically induced. Male. Metallothionein / genetics. Nervous System Neoplasms / chemically induced. O(6)-Methylguanine-DNA Methyltransferase / genetics. Pregnancy. RNA, Messenger / genetics. RNA, Messenger / metabolism. Rats. Rats, Inbred F344. Rats, Inbred LEC. Rats, Long-Evans. Species Specificity

  • Hazardous Substances Data Bank. N-NITROSO-N-ETHYLUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19763020.001).
  • [ISSN] 1349-6867
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinogens; 0 / RNA, Messenger; 0 / metallothionein 2 protein, rat; 9038-94-2 / Metallothionein; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; P8M1T4190R / Ethylnitrosourea
  •  go-up   go-down


79. Evans DG: Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis; 2009;4:16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type 2 (NF2): a clinical and molecular review.
  • Neurofibromatosis type 2 (NF2) is a tumour-prone disorder characterised by the development of multiple schwannomas and meningiomas.
  • Affected individuals inevitably develop schwannomas, typically affecting both vestibular nerves and leading to hearing loss and deafness.
  • Vestibular schwannomas may also cause dizziness or imbalance as a first symptom.
  • Nausea, vomiting or true vertigo are rare symptoms, except in late-stage disease.
  • The other main tumours are schwannomas of the other cranial, spinal and peripheral nerves; meningiomas both intracranial (including optic nerve meningiomas) and intraspinal, and some low-grade central nervous system malignancies (ependymomas).
  • Neurofibromatosis type 2 is a dominantly inherited tumour predisposition syndrome caused by mutations in the NF2 gene on chromosome 22.
  • More than 50% of patients represent new mutations and as many as one-third are mosaic for the underlying disease-causing mutation.
  • Although truncating mutations (nonsense and frameshifts) are the most frequent germline event and cause the most severe disease, single and multiple exon deletions are common.
  • A strategy for detection of the latter is vital for a sensitive analysis.
  • NF2 represents a difficult management problem with most patients facing substantial morbidity and reduced life expectancy.
  • In the future, the development of tailored drug therapies aimed at the genetic level are likely to provide huge improvements for this devastating condition.


80. Rice JM, Wilbourn JD: Tumors of the nervous system in carcinogenic hazard identification. Toxicol Pathol; 2000 Jan-Feb;28(1):202-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the absence of adequate data on humans, it is biologically plausible and prudent to regard agents and mixtures for which there is sufficient evidence of carcinogenicity in experimental animals, usually rats and mice, as if they presented a carcinogenic risk to humans.
  • However, CNS tumors have been readily induced in rodents by systemic exposures to some chemicals, notably N-nitrosoalkylureas and other alkylating agents and certain alkyl hydrazine derivatives.
  • CNS tumors in rodents have played a significant role in carcinogenic hazard evaluations of several other chemicals, including acrylonitrile, ethylene oxide, and acrylamide, and have been implicated as part of the tumor spectrum induced by vinyl chloride and certain inorganic lead compounds.
  • Diagnostic difficulties have been presented by undifferentiated small-cell tumors that may invade the brain, including carcinomas of the nasal cavity and undifferentiated schwannomas arising in cranial nerve ganglia, and by the difficulty of reliably distinguishing between focal reactive gliosis and early glial neoplasms.
  • The most striking experimental finding regarding the induction by chemicals of tumors of the nervous system is the dramatically greater susceptibility of the fetal and neonatal nervous system to some carcinogens, as compared with the susceptibility of the nervous system in adults of the same species.
  • [MeSH-minor] Animals. Humans. Mice. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10669008.001).
  • [ISSN] 0192-6233
  • [Journal-full-title] Toxicologic pathology
  • [ISO-abbreviation] Toxicol Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens
  • [Number-of-references] 72
  •  go-up   go-down


81. Koerbel A, Gharabaghi A, Samii A, Gerganov V, von Gösseln H, Tatagiba M, Samii M: Trigeminocardiac reflex during skull base surgery: mechanism and management. Acta Neurochir (Wien); 2005 Jul;147(7):727-32; discussion 732-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FINDINGS: Sixteen patients (8%) had a TCR intra-operatively (7 vestibular schwannomas, 5 sphenoid wing meningiomas, 3 petroclival meningiomas, 1 intracavernous epidermoid cyst).
  • This technique is sufficient for the heart rate and the arterial blood pressure to return to normal levels without the necessity of additional anticholinergic medication.

  • MedlinePlus Health Information. consumer health - Low Blood Pressure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15889318.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


82. Prkacin I, Martinac M, Sabljar-Matovinović M, Skegro D, Mazalin J: Pelvic neurilemmoma. Acta Med Croatica; 2001;55(2):97-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic neurilemmoma.
  • A case of a 37-year-old man admitted to our Department of Internal Medicine for medical evaluation of hypertension is reported.
  • On routine ultrasonography of the pelvis confirmed a pelvic tumor of uncertain etiology, with no abdominal lymph node enlargement.
  • The patient was transferred to the Department of Surgery, where the tumor was removed in toto.
  • Histopathologic analysis of the tumor, 11 x 8 x 8 cm in size, composed of cellular and mixoid areas with traces of collagenous connective tissue, necrosis, and tiny calcifications with scattered palisading nuclei and Verocay bodies, pointed to the diagnosis of a benign tumor, i.e. neurilemmoma.
  • To our knowledge, pelvic localization of neurilemmoma, particularly a large one, is rare.
  • [MeSH-major] Neurilemmoma. Pelvic Neoplasms. Retroperitoneal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11505636.001).
  • [ISSN] 1330-0164
  • [Journal-full-title] Acta medica Croatica : c̆asopis Hravatske akademije medicinskih znanosti
  • [ISO-abbreviation] Acta Med Croatica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


83. Sousa MM, Cardoso I, Fernandes R, Guimarães A, Saraiva MJ: Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol; 2001 Dec;159(6):1993-2000
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Familial amyloidotic polyneuropathy (FAP) is a neurodegenerative disorder characterized by extracellular deposition of transthyretin (TTR) amyloid fibrils, particularly in the peripheral nervous system.
  • We assessed nerves from FAP patients in different stages of disease progression (FAP 0 to FAP 3) for TTR deposition by immunohistochemistry, and for the presence of amyloid fibrils by Congo Red staining.
  • Toxicity of synthetic TTR fibrils formed in vitro at physiological pH was studied on a Schwannoma cell line by caspase-3 activation assays and showed that early aggregates but not mature fibrils are toxic to cells.
  • [MeSH-minor] Adolescent. Adult. Amyloid / metabolism. Animals. Caspase 3. Caspases / drug effects. Caspases / metabolism. Cell Line. Disease Progression. Enzyme Activation / drug effects. Humans. Immunohistochemistry. Macrophage Colony-Stimulating Factor / metabolism. Microscopy, Electron. Middle Aged. Sural Nerve / chemistry. Sural Nerve / pathology. Sural Nerve / ultrastructure

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 1999 Sep 14;883:77-90 [10586234.001]
  • [Cites] Amyloid. 1998 Sep;5(3):163-74 [9818053.001]
  • [Cites] J Neurol Sci. 2000 Mar 1;174(1):16-21 [10704976.001]
  • [Cites] JAMA. 2000 Mar 22-29;283(12):1571-7 [10735393.001]
  • [Cites] Lab Invest. 2000 Jul;80(7):1101-10 [10908156.001]
  • [Cites] Endocrinology. 2000 Aug;141(8):2914-22 [10919279.001]
  • [Cites] J Peripher Nerv Syst. 1996;1(3):179-88 [10970108.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27207-13 [11306576.001]
  • [Cites] Brain. 1971;94(2):199-206 [4328329.001]
  • [Cites] Brain. 1971;94(2):207-12 [4328330.001]
  • [Cites] J Mol Biol. 1978 May 25;121(3):339-56 [671542.001]
  • [Cites] J Lab Clin Med. 1983 Oct;102(4):590-603 [6311926.001]
  • [Cites] J Clin Invest. 1984 Jul;74(1):104-19 [6736244.001]
  • [Cites] Biochem Biophys Res Commun. 1985 Mar 29;127(3):890-5 [3838668.001]
  • [Cites] J Clin Invest. 1985 Dec;76(6):2171-7 [3908483.001]
  • [Cites] J Biochem. 1986 Nov;100(5):1215-22 [3818577.001]
  • [Cites] Nature. 1996 Aug 22;382(6593):685-91 [8751438.001]
  • [Cites] Structure. 1996 Aug 15;4(8):989-98 [8805583.001]
  • [Cites] Endocrine. 1997 Jun;6(3):309-15 [9368688.001]
  • [Cites] J Biol Chem. 1998 Sep 18;273(38):24715-22 [9733771.001]
  • [Cites] Ann Neurol. 1999 Dec;46(6):860-6 [10589538.001]
  • (PMID = 11733349.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid; 0 / Prealbumin; 81627-83-0 / Macrophage Colony-Stimulating Factor; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC1850610
  •  go-up   go-down


84. Steinhart H, Zenk J, Sprang K, Bozzato A, Iro H: Contrast-enhanced color Doppler sonography of parotid gland tumors. Eur Arch Otorhinolaryngol; 2003 Jul;260(6):344-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of the present study is to assess the potential of color Doppler sonography in imaging tumors of the parotid gland enhanced by application of ultrasound contrast agents.
  • The color Doppler signal areas before and after administration of Doppler signal-enhancing agent (Levovist, Schering, Germany) were determined by means of computer-assisted analysis, and the relevant parameters were evaluated.
  • The tumors can be classified as follows: 11 pleomorphic adenomas, 8 adenolymphomas and two squamous cell carcinomas of the parotid gland, two lymph nodes, one adenoma, one neurinoma of the facial nerve and one non-Hodgkin's lymphoma.
  • Before the administration of Doppler signal-enhancing agent, the adenolymphomas showed a significantly stronger Doppler signal area as compared to the pleomorphic adenomas.
  • The maximum color Doppler signal area after administration of Doppler signal-enhancing agent showed no difference within both groups.
  • If one considers the relative change in the Doppler signal area before and after applying enhancing agent, however, a significantly stronger enhancement of perfusion (increase in Doppler signal area) is noted within pleomorphic adenomas.
  • The changes in the Doppler signal area after administration of signal-enhancing agent show a different course depending on the histology of the investigated tumors.
  • [MeSH-major] Adenolymphoma / diagnostic imaging. Adenoma, Pleomorphic / diagnostic imaging. Carcinoma, Squamous Cell / diagnostic imaging. Parotid Neoplasms / diagnostic imaging. Ultrasonography, Doppler, Color

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 1998 Aug;71(848):828-33 [9828794.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2000;257(8):453-8 [11073198.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1994;251(7):404-9 [7857628.001]
  • [Cites] AJR Am J Roentgenol. 1994 Oct;163(4):933-41 [8092039.001]
  • [Cites] J Laryngol Otol. 1999 Nov;113(11):988-92 [10696376.001]
  • [Cites] Rofo. 1994 May;160(5):397-405 [8173049.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 Nov-Dec;19(10 ):1835-9 [9874532.001]
  • [Cites] J Clin Ultrasound. 1976 Feb;4(1):11-3 [175095.001]
  • [Cites] AJR Am J Roentgenol. 1989 Jul;153(1):161-6 [2660533.001]
  • [Cites] Eur Radiol. 1998;8(8):1462-7 [9853238.001]
  • [Cites] Laryngorhinootologie. 1993 Apr;72 (4):187-92 [8494590.001]
  • [Cites] Eur J Surg Oncol. 1992 Oct;18(5):463-8 [1330705.001]
  • [Cites] Geburtshilfe Frauenheilkd. 1993 Dec;53(12):866-9 [8119570.001]
  • [Cites] HNO. 1995 Jan;43(1):25-30 [7890547.001]
  • [Cites] AJR Am J Roentgenol. 2000 May;174(5):1279-84 [10789776.001]
  • [Cites] Eur J Ultrasound. 2000 Dec;12 (2):123-30 [11118919.001]
  • [Cites] Am J Otolaryngol. 1997 Jul-Aug;18(4):254-7 [9242876.001]
  • (PMID = 12883961.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


85. Plotkin SR, Halpin C, Blakeley JO, Slattery WH 3rd, Welling DB, Chang SM, Loeffler JS, Harris GJ, Sorensen AG, McKenna MJ, Barker FG 2nd: Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol; 2009 May;93(1):61-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.
  • Neurofibromatosis type 2 (NF2) is a tumor suppressor gene syndrome characterized by multiple schwannomas, especially vestibular schwannomas (VS), and meningiomas.
  • Anticancer drug trials are now being explored, but there are no standardized endpoints in NF2.
  • We also identify research goals in NF2 to facilitate future trial conduct, such as identifying the expectations for time to tumor progression and time to measurable hearing loss in untreated NF2-related VS, and the relation of both endpoints to patient prognostic factors (such as age, baseline tumor volume, and measures of disease severity).
  • These data would facilitate future use of endpoints based on stability of tumor size and hearing, which might be more appropriate for testing certain drugs.
  • We encourage adoption of standardized endpoints early in the development of phase II trials for this population to facilitate comparison of results across trials of different agents.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Clinical Trials, Phase II as Topic / standards. Neurofibromatosis 2 / complications. Neurofibromatosis 2 / drug therapy. Neuroma, Acoustic / drug therapy

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2007 Jan;9(1):29-38 [17108063.001]
  • [Cites] Neurol Med Chir (Tokyo). 2006 Dec;46(12):601-4 [17185887.001]
  • [Cites] Audiol Neurootol. 2007;12(1):1-12 [17033159.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):972-6 [17277252.001]
  • [Cites] Neurosurgery. 2007 Mar;60(3):460-8; discussion 468-70 [17327790.001]
  • [Cites] Acta Neurochir (Wien). 2007 Mar;149(3):267-73; discussion 273 [17342379.001]
  • [Cites] J Am Acad Audiol. 2007 Feb;18(2):151-83 [17402301.001]
  • [Cites] Mol Cancer Ther. 2007 Apr;6(4):1180-5 [17431101.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1753-9 [17470865.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1760-4 [17470866.001]
  • [Cites] Ear Hear. 2007 Apr;28(2):187-95 [17496670.001]
  • [Cites] Pediatr Neurol. 2007 May;36(5):293-300 [17509460.001]
  • [Cites] BMC Cancer. 2007;7:106 [17587447.001]
  • [Cites] Int J Audiol. 2007 Aug;46(8):442-8 [17654086.001]
  • [Cites] N Engl J Med. 1998 Nov 12;339(20):1426-33 [9811917.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2007 Oct;15(5):341-6 [17823551.001]
  • [Cites] Pediatrics. 2007 Nov;120(5):1044-52 [17974742.001]
  • [Cites] Otol Neurotol. 2007 Dec;28(8):1083-90 [18043434.001]
  • [Cites] Am J Otol. 2000 Sep;21(5):722-8 [10993466.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Sep;21(8):1540-6 [11003293.001]
  • [Cites] Laryngoscope. 2000 Nov;110(11):1843-9 [11081597.001]
  • [Cites] Scand Audiol. 2000;29(4):266-75 [11195947.001]
  • [Cites] Radiother Oncol. 2001 Jul;60(1):45-8 [11410303.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2001 Oct;26(5):388-93 [11678946.001]
  • [Cites] Otol Neurotol. 2001 Nov;22(6):917-21 [11698819.001]
  • [Cites] Laryngoscope. 2001 Nov;111(11 Pt 2 Suppl 98):1-21 [11802001.001]
  • [Cites] J Neurosurg. 2002 Feb;96(2):217-22 [11838793.001]
  • [Cites] J Neurosurg. 2002 Feb;96(2):223-8 [11838794.001]
  • [Cites] J Neurosurg. 2002 Apr;96(4):796-800 [11990824.001]
  • [Cites] Am J Hum Genet. 2002 Oct;71(4):715-23 [12235555.001]
  • [Cites] Int J Audiol. 2002 Dec;41(8):535-44 [12477174.001]
  • [Cites] Laryngoscope. 2003 Mar;113(3):420-6 [12616190.001]
  • [Cites] Int J Audiol. 2003 Apr;42(3):152-60 [12705780.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2003 May;112(5):395-7 [12784975.001]
  • [Cites] Otol Neurotol. 2003 May;24(3):465-8 [12806300.001]
  • [Cites] Laryngoscope. 2003 Aug;113(8):1332-43 [12897555.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1288-93 [12933938.001]
  • [Cites] J Neurosurg. 2003 Sep;99(3):480-3 [12959433.001]
  • [Cites] Gerontologist. 2003 Oct;43(5):661-8 [14570962.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2003 Oct;260(9):487-9 [12736745.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2003 Nov;112(11):979-86 [14653368.001]
  • [Cites] Virchows Arch. 2003 Dec;443(6):768-73 [14508685.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):323-7 [14974864.001]
  • [Cites] Otol Neurotol. 2004 Mar;25(2):150-4 [15021775.001]
  • [Cites] Laryngoscope. 2004 May;114(5):814-20 [15126736.001]
  • [Cites] Neurochirurgie. 2004 Jun;50(2-3 Pt 2):312-9 [15179284.001]
  • [Cites] Neurology. 2004 Aug 10;63(3):535-7 [15304589.001]
  • [Cites] Otol Neurotol. 2004 Sep;25(5):811-7 [15354016.001]
  • [Cites] Tech Rep SAM-TR. 1966 Jun;:1-12 [5296571.001]
  • [Cites] J Speech Hear Res. 1978 Sep;21(3):507-18 [713519.001]
  • [Cites] Neurosurgery. 1980 Aug;7(2):154-9 [6968414.001]
  • [Cites] Neurosurg Clin N Am. 1999 Apr;10(2):305-15 [10099095.001]
  • [Cites] Neurol Med Chir (Tokyo). 1999 Feb;39(2):141-7; discussion 147-9 [10193147.001]
  • [Cites] J Speech Hear Disord. 1952 Sep;17(3):321-37 [13053556.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):339-48 [15578712.001]
  • [Cites] Otol Neurotol. 2005 Jan;26(1):93-7 [15699726.001]
  • [Cites] Otol Neurotol. 2005 Jan;26(1):98-101 [15699727.001]
  • [Cites] Laryngoscope. 2005 Mar;115(3):450-4 [15744156.001]
  • [Cites] Otol Neurotol. 2005 Mar;26(2):188-95 [15793403.001]
  • [Cites] Otol Neurotol. 2005 May;26(3):512-5 [15891658.001]
  • [Cites] Otol Neurotol. 2005 Jul;26(4):733-40 [16015177.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5094-8 [15983399.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):75-81 [16111574.001]
  • [Cites] J Neurosurg. 2005 Jul;103(1):59-63 [16121974.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7199-206 [16192604.001]
  • [Cites] J Med Genet. 2005 Dec;42(12):903-6 [15831594.001]
  • [Cites] Otol Neurotol. 2006 Jan;27(1):110-6 [16371857.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(1):CD003998 [16437471.001]
  • [Cites] Otol Neurotol. 2006 Feb;27(2):197-208 [16436990.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):38-46 [16443946.001]
  • [Cites] Neurosurgery. 2006 Feb;58(2):241-8; discussion 241-8 [16462477.001]
  • [Cites] J Neurosurg. 2006 Jan;104(1):157-62 [16509161.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1966-9 [16609005.001]
  • [Cites] Otol Neurotol. 2006 Apr;27(3):403-9 [16639281.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2006 Mar;263(3):267-70 [16025257.001]
  • [Cites] Neurosurgery. 2006 Jun;58(6):1119-28; discussion 1119-28 [16723891.001]
  • [Cites] Otol Neurotol. 2006 Jun;27(4):547-52 [16791048.001]
  • [Cites] Neurosurgery. 2006 Jul;59(1):67-76; discussion 67-76 [16823302.001]
  • [Cites] Otol Neurotol. 2006 Aug;27(5):705-12 [16868519.001]
  • [Cites] Lancet Oncol. 2006 Sep;7(9):741-6 [16945769.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2006 Sep;115(9):694-8 [17044542.001]
  • [Cites] Neurology. 2006 Nov 28;67(10):1860-2 [17035676.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Audiology. 1984;23(6):552-68 [6517748.001]
  • [Cites] Otolaryngol Head Neck Surg. 1985 Apr;93(2):146-7 [3921901.001]
  • [Cites] Arch Dermatol. 1987 Aug;123(8):1011-6 [3115189.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1988 Jan;114(1):85-7 [3334825.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1988 Jan-Feb;97(1):55-66 [3277525.001]
  • [Cites] Otolaryngol Head Neck Surg. 1988 Apr;98(4):273-82 [3132678.001]
  • [Cites] J Am Geriatr Soc. 1990 Jan;38(1):45-50 [2295767.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Otolaryngol Head Neck Surg. 1990 Dec;103(6):963-5 [2126130.001]
  • [Cites] Neurosurgery. 1991 May;28(5):646-50; discussion 650-1 [1876241.001]
  • [Cites] Neurosurgery. 1992 Nov;31(5):829-38; discussion 838-9 [1436407.001]
  • [Cites] J Med Genet. 1992 Dec;29(12):841-6 [1479598.001]
  • [Cites] Q J Med. 1992 Aug;84(304):603-18 [1484939.001]
  • [Cites] Acta Otolaryngol Suppl. 1991;487:91-8 [1843593.001]
  • [Cites] J Neuropathol Exp Neurol. 1993 Mar;52(2):106-13 [8440992.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1993 Jul;102(7):518-20 [8333673.001]
  • [Cites] J Neurosurg. 1994 Mar;80(3):541-7 [8113868.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Jul;113(1):5-14 [7603722.001]
  • [Cites] Neuroradiology. 1995 May;37(4):317-20 [7666970.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Sep;113(3):176-8 [7675474.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Sep;113(3):179-80 [7675475.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):1018-26 [8622006.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1996 Jun;105(6):415-22 [8638891.001]
  • [Cites] Laryngoscope. 1996 Jun;106(6):694-9 [8656953.001]
  • [Cites] Ir J Med Sci. 1996 Jul-Sep;165(3):151-2 [8824013.001]
  • [Cites] Neurosurgery. 1997 Apr;40(4):696-705; discussion 705-6 [9092842.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Feb;18(2):313-23 [9111669.001]
  • [Cites] J Neurosurg. 1997 Jul;87(1):60-6 [9202266.001]
  • [Cites] Am J Otol. 1997 Jul;18(4):421-6 [9233480.001]
  • [Cites] Am J Otol. 1997 Jul;18(4):427-35 [9233481.001]
  • [Cites] Surg Neurol. 1997 Oct;48(4):395-400 [9315139.001]
  • [Cites] Eur J Cancer. 1997 Dec;33(14):2326-32 [9616276.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1785(1):32-54 [17980164.001]
  • [Cites] Otol Neurotol. 2008 Jan;29(1):50-7 [18199957.001]
  • [Cites] Brain. 2008 Mar;131(Pt 3):606-15 [17940085.001]
  • [Cites] J Clin Oncol. 2008 Mar 10;26(8):1346-54 [18285606.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Mar;29(3):419-24 [18272557.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):431-6 [17673492.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):1987-92 [18421050.001]
  • [Cites] Otolaryngol Head Neck Surg. 2008 May;138(5):667-71 [18439476.001]
  • [Cites] Lancet Oncol. 2008 May;9(5):453-61 [18452856.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):162-70 [18356283.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 May;29(5):906-10 [18296549.001]
  • [Cites] Clin Otolaryngol. 2008 Jun;33(3):255-9 [18559034.001]
  • [Cites] Acta Neurochir Suppl. 2008;101:169-73 [18642654.001]
  • [Cites] Neuro Oncol. 2008 Aug;10(4):631-42 [18559968.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Aug;5(8):487-91 [18560388.001]
  • [Cites] Otol Neurotol. 2008 Aug;29(5):615-21 [18451751.001]
  • [Cites] Acta Oncol. 2008;47(6):1171-3 [18615326.001]
  • [Cites] Prog Neurol Surg. 2008;21:176-82 [18810217.001]
  • [Cites] Neurosurgery. 2008 Jun;62(6):1314-9; discussion 1319-20 [18824998.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Nov;5(11):634-44 [18711427.001]
  • [Cites] Clin Otolaryngol. 2008 Oct;33(5):427-34 [18983375.001]
  • [Cites] Curr Opin Neurol. 2008 Dec;21(6):728-35 [18989120.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):390-8 [19109818.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2009 Jun;266(6):907-17 [19005632.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Laryngoscope. 2000 Feb;110(2 Pt 1):250-5 [10680925.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Apr;122(4):602-6 [10740189.001]
  • [Cites] Am J Otol. 2000 May;21(3):393-8 [10821554.001]
  • [Cites] Surg Neurol. 2000 Apr;53(4):383-89; discussion 389-90 [10825525.001]
  • [Cites] Rev Laryngol Otol Rhinol (Bord). 2000;121(1):21-6 [10865479.001]
  • [Cites] Lancet. 2000 Jul 29;356(9227):373-8 [10972369.001]
  • (PMID = 19430883.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 154
  • [Other-IDs] NLM/ NIHMS573252; NLM/ PMC4036446
  •  go-up   go-down


86. Mattingly RR, Kraniak JM, Dilworth JT, Mathieu P, Bealmear B, Nowak JE, Benjamins JA, Tainsky MA, Reiners JJ Jr: The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines. J Pharmacol Exp Ther; 2006 Jan;316(1):456-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines.
  • Type 1 neurofibromatosis (NF1) is a common autosomal dominant disorder that results in neuroectodermal tumors.
  • The NF1 tumor-suppressor gene encodes neurofibromin, which includes a GTPase-activating domain for Ras inactivation.
  • Affinity purification showed N-Ras to be the predominant activated isoform of Ras in two independent neurofibrosarcoma cell lines from NF1 patients (lines ST88-14 and NF90-8).
  • These NF1 cells also demonstrated increased constitutive activity of the extracellular signal-regulated kinases 1 and 2 (ERK1,2) mitogen-activated protein (MAP) kinases compared with a sporadic malignant schwannoma cell line that maintains neurofibromin expression (STS-26T).
  • The MEK inhibitors PD98059 [2'-amino-3'-methoxyflavone], PD184352 (also called CI-1040) [2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide], and U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene] all produced concentration-dependent suppression of the proliferation of the three cell lines.
  • Individual MEK inhibitors had similar effects in all three cell lines.
  • The differential effects of the MEK inhibitors on cell survival were not dependent on p53 status or effects on the ERK5 pathway.
  • PD184352 was also proapoptotic to primary rat Schwann cells.
  • Hence, although PD184352 effectively killed neurofibrosarcoma cells, its effects on normal Schwann cells may limit its usefulness in the clinic.
  • [MeSH-major] Apoptosis / drug effects. Benzamides / pharmacology. Enzyme Inhibitors / pharmacology. Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors. Neurilemmoma / pathology
  • [MeSH-minor] Blotting, Western. Butadienes / pharmacology. Cell Line, Tumor. Cell Proliferation / drug effects. Flavonoids / pharmacology. Flow Cytometry. Gene Expression Regulation, Neoplastic / drug effects. Genes, p53 / genetics. Genes, ras / genetics. Humans. Mitogen-Activated Protein Kinase 7 / metabolism. Neurofibromatosis 1 / pathology. Nitriles / pharmacology. Phosphorylation. Reverse Transcriptase Polymerase Chain Reaction. Transfection


87. Cardoso I, Merlini G, Saraiva MJ: 4'-iodo-4'-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J; 2003 May;17(8):803-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transthyretin Leu55Pro is one of the most aggressive mutations in familial amyloidotic polyneuropathy, an autosomal dominant disorder characterized by extracellular deposition of fibrillar amyloid protein.
  • We studied by transmission electron microscopy the effect of the drug 4'-iodo-4'-deoxydoxorubicin (I-DOX) on the in vitro assembly of TTR Leu55Pro fibrils by following fibril growth over a 15 day period.
  • The species generated upon I-DOX and tetracyclines treatments were nontoxic, as revealed by the lack of significant caspase-3 activation on a Schwannoma cell line, making them potential therapeutic drugs in TTR-related and other amyloidosis.
  • [MeSH-minor] Amino Acid Substitution. Animals. Caspase 3. Caspases / metabolism. Cell Survival / drug effects. Doxycycline / pharmacology. Drug Evaluation, Preclinical / methods. Enzyme Activation / drug effects. Leucine / genetics. Microscopy, Electron. Mutation. Nitrophenols / pharmacology. Proline / genetics. Rolitetracycline / pharmacology. Tumor Cells, Cultured / drug effects

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • Hazardous Substances Data Bank. L-Leucine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12724338.001).
  • [ISSN] 1530-6860
  • [Journal-full-title] FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • [ISO-abbreviation] FASEB J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid; 0 / Nitrophenols; 0 / Prealbumin; 0 / Tetracyclines; 80168379AG / Doxorubicin; 83997-75-5 / 4'-deoxy-4'-iododoxorubicin; 9DLQ4CIU6V / Proline; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; GH9IW85221 / Rolitetracycline; GMW67QNF9C / Leucine; N12000U13O / Doxycycline
  •  go-up   go-down


88. Demestre M, Messerli SM, Celli N, Shahhossini M, Kluwe L, Mautner V, Maruta H: CAPE (caffeic acid phenethyl ester)-based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice. Phytother Res; 2009 Feb;23(2):226-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CAPE (caffeic acid phenethyl ester)-based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice.
  • Dysfunction of the NF1 gene coding a RAS GAP is the major cause of neurofibromatosis type 1 (NF1), whereas neurofibromatosis type 2 (NF2) is caused primarily by dysfunction of the NF2 gene product called merlin that inhibits directly PAK1, an oncogenic Rac/CDC42-dependent Ser/Thr kinase.
  • Thus, several anti-PAK1 drugs, including FK228 and CEP-1347, are being developed for the treatment of NF tumors.
  • Since propolis, a very safe healthcare product from bee hives, contains anticancer ingredients called CAPE (caffeic acid phenethyl ester) or ARC (artepillin C), depending on the source, both of which block the oncogenic PAK1 signaling pathways, its potential therapeutic effect on NF tumors was explored in vivo.
  • Here it is demonstrated that Bio 30, a CAPE-rich water-miscible extract of New Zealand (NZ) propolis suppressed completely the growth of a human NF1 cancer called MPNST (malignant peripheral nerve sheath tumor) and caused an almost complete regression of human NF2 tumor (Schwannoma), both grafted in nude mice.
  • Although CAPE alone has never been used clinically, due to its poor bioavailability/water-solubility, Bio 30 contains plenty of lipids which solubilize CAPE, and also includes several other anticancer ingredients that seem to act synergistically with CAPE.
  • Thus, it would be worth testing clinically to see if Bio 30 and other CAPE-rich propolis are useful for the treatment of NF patients.
  • [MeSH-major] Caffeic Acids / pharmacology. Neurofibromatosis 1 / drug therapy. Neurofibromatosis 2 / drug therapy. Phenylethyl Alcohol / analogs & derivatives. Propolis / pharmacology. Xenograft Model Antitumor Assays
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Female. Humans. Mice. Mice, Nude. p21-Activated Kinases / antagonists & inhibitors

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Hazardous Substances Data Bank. 2-PHENYLETHANOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 John Wiley & Sons, Ltd.
  • (PMID = 18726924.001).
  • [ISSN] 1099-1573
  • [Journal-full-title] Phytotherapy research : PTR
  • [ISO-abbreviation] Phytother Res
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P41 RR001395
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Caffeic Acids; 9009-62-5 / Propolis; EC 2.7.11.1 / PAK1 protein, human; EC 2.7.11.1 / p21-Activated Kinases; G960R9S5SK / caffeic acid phenethyl ester; ML9LGA7468 / Phenylethyl Alcohol
  •  go-up   go-down


89. Sakamoto T, Shirato H, Takeichi N, Aoyama H, Kagei K, Nishioka T, Fukuda S: Medication for hearing loss after fractionated stereotactic radiotherapy (SRT) for vestibular schwannoma. Int J Radiat Oncol Biol Phys; 2001 Aug 1;50(5):1295-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medication for hearing loss after fractionated stereotactic radiotherapy (SRT) for vestibular schwannoma.
  • PURPOSE: To investigate the effectiveness of corticosteroid treatments for patients showing decreases in hearing levels after stereotactic radiotherapy for vestibular schwannoma.
  • The hearing recovery rate, normalizing to the degree of the hearing loss before medication, was also significantly higher in the medicated group than in the nonmedicated group (p = 0.0014).
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Hearing Loss, Sensorineural / drug therapy. Neuroma, Acoustic / surgery. Prednisone / therapeutic use. Radiation Injuries / drug therapy. Radiosurgery / adverse effects. Vestibular Nerve / radiation effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Audiometry, Pure-Tone. Dose Fractionation. Drug Evaluation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11483341.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; VB0R961HZT / Prednisone
  •  go-up   go-down


90. Murakami T, Funatsuka M, Komine M, Hirayama Y, Suzuki H, Shishikura K, Aihara Y, Shibata K, Hori T, Kobayashi M, Osawa M: Oculomotor nerve schwannoma mimicking ophthalmoplegic migraine. Neuropediatrics; 2005 Dec;36(6):395-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oculomotor nerve schwannoma mimicking ophthalmoplegic migraine.
  • We describe a case of an 11-year-old girl with pathologically confirmed oculomotor nerve schwannoma who had been suffering from symptoms mimicking OM.
  • In contrast, however, her attacks became more frequent and were not controlled by medication.
  • From this experience, we hypothesize that optic nerve tumor is one condition that can mimic OM, without apparent signs suggestive of intracranial mass.
  • To our knowledge, this is the first report to describe a pathologically confirmed case of oculomotor nerve schwannoma mimicking OM.
  • [MeSH-major] Migraine Disorders / etiology. Neurilemmoma / complications. Oculomotor Nerve Diseases / etiology. Ophthalmoplegia / etiology. Optic Nerve Neoplasms / complications

  • Genetic Alliance. consumer health - Migraine.
  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Migraine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16429381.001).
  • [ISSN] 0174-304X
  • [Journal-full-title] Neuropediatrics
  • [ISO-abbreviation] Neuropediatrics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


91. Pavel E, Nadella K, Towns WH 2nd, Kirschner LS: Mutation of Prkar1a causes osteoblast neoplasia driven by dysregulation of protein kinase A. Mol Endocrinol; 2008 Feb;22(2):430-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carney complex (CNC) is an autosomal dominant neoplasia syndrome caused by inactivating mutations in PRKAR1A, the gene encoding the type 1A regulatory subunit of protein kinase A (PKA).
  • This genetic defect induces skin pigmentation, endocrine tumors, myxomas, and schwannomas.
  • To study the link between the PRKAR1A mutations and tumor formation, we generated a mouse model of this condition.
  • To better understand these cells at the biochemical level, we isolated primary cultures of tumoral bone and compared them with cultures of bone from wild-type animals.
  • The tumor cells exhibited the expected decrease in Prkar1a protein and exhibited increased PKA activity.
  • At the phenotypic level, we observed that tumor cells behaved as incompletely differentiated osteoblasts and were able to form tumors in immunocompromised mice.
  • Tumor cells exhibited enhanced growth in response to PKA-stimulating agents, suggesting that tumorigenesis in osteoblast precursor cells is driven by effects directly mediated by the dysregulation of PKA.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1999 Jan;187(2):249-58 [10365102.001]
  • [Cites] Front Biosci. 2007;12:3068-92 [17485283.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8811-5 [15604237.001]
  • [Cites] Transplantation. 2005 Feb 27;79(4):392-400 [15729164.001]
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] J Bone Miner Res. 2000 Jan;15(1):120-8 [10646121.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):89-92 [10973256.001]
  • [Cites] J Clin Invest. 2000 Sep;106(5):R31-8 [10974026.001]
  • [Cites] Hum Mol Genet. 2000 Dec 12;9(20):3037-46 [11115848.001]
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):164-76 [11176065.001]
  • [Cites] Plast Reconstr Surg. 2001 Dec;108(7):2026-39; discussion 2040-6 [11743396.001]
  • [Cites] Genome Biol. 2002;3(1):REVIEWS3001 [11806834.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):27294-304 [12004056.001]
  • [Cites] Nature. 2002 Sep 12;419(6903):162-7 [12226664.001]
  • [Cites] Genome Biol. 2003;4(10):R67 [14519202.001]
  • [Cites] Ann Rheum Dis. 2004 Mar;63(3):252-8 [14962958.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 2004;14(1-2):1-41 [15104525.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14222-7 [15371594.001]
  • [Cites] Surgery. 1993 Feb;113(2):130-3 [8430361.001]
  • [Cites] J Histochem Cytochem. 1994 Jun;42(6):733-44 [8189035.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Sep;79(3):750-5 [8077356.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):19-26 [7712644.001]
  • [Cites] J Bone Miner Res. 1997 Feb;12(2):172-8 [9041048.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1587-600 [9403710.001]
  • [Cites] J Clin Invest. 1998 Apr 15;101(8):1737-44 [9541505.001]
  • [Cites] J Biol Chem. 1998 Sep 4;273(36):23469-75 [9722584.001]
  • [Cites] Gene. 2004 Oct 27;341:19-39 [15474285.001]
  • [Cites] Medicine (Baltimore). 1985 Jul;64(4):270-83 [4010501.001]
  • [Cites] Biochem Biophys Res Commun. 1991 May 31;177(1):365-9 [1645960.001]
  • [Cites] Vet Pathol. 1991 Sep;28(5):381-8 [1750163.001]
  • [Cites] Science. 1992 Mar 13;255(5050):1434-7 [1542794.001]
  • [Cites] J Immunol. 1992 Jun 15;148(12):4066-71 [1602143.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4506-14 [15930266.001]
  • [Cites] J Cell Biochem. 2005 Aug 15;95(6):1178-90 [15962290.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10307-15 [16288019.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Feb;91(2):584-96 [16278264.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1140-9 [16670754.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1202-9 [16670761.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2380-8 [16569736.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):794-800 [16767104.001]
  • [Cites] J Bone Miner Res. 2006 Dec;21 Suppl 2:P125-31 [17229001.001]
  • [Cites] J Med Genet. 2004 Dec;41(12):923-31 [15591278.001]
  • (PMID = 17932105.001).
  • [ISSN] 0888-8809
  • [Journal-full-title] Molecular endocrinology (Baltimore, Md.)
  • [ISO-abbreviation] Mol. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112268; United States / NICHD NIH HHS / HD / K22 HD001323; United States / NCI NIH HHS / CA / CA 16058; United States / NICHD NIH HHS / HD / HD 01323; United States / NCI NIH HHS / CA / P30 CA016058; United States / NCI NIH HHS / CA / CA 112268-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; 0 / Prkar1a protein, mouse; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases
  • [Other-IDs] NLM/ PMC2234582
  •  go-up   go-down


92. Kumagai D, Yamate J, Tajima T, Tsukamoto Y, Yasui H, Kuwamura M, Kotani T, Sakuma S: Distribution of cells labelled by a monoclonal antibody (A3) against a cloned cell line derived from a rat malignant fibrous histiocytoma. J Comp Pathol; 2000 Aug-Oct;123(2-3):77-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of cells labelled by a monoclonal antibody (A3) against a cloned cell line derived from a rat malignant fibrous histiocytoma.
  • To pursue the histogenesis of malignant fibrous histiocytoma (MFH), of which the cell of origin is still debated, a monoclonal antibody (A3) was produced against a rat MFH-derived cloned cell line (MT-8).
  • A3 reacted specifically with MT-8 cells, with another rat MFH-derived cell line (MT-9) and with their induced tumours in syngeneic rats, but not with other rat tumours such as fibrosarcoma, histiocytic sarcoma, malignant meningioma, uterine leiomyosarcoma, endometrial stromal sarcoma, mononuclear cell leukaemia and malignant schwannoma.
  • [MeSH-major] Antibodies, Monoclonal / pharmacokinetics. Histiocytoma, Benign Fibrous / metabolism
  • [MeSH-minor] Animals. Aorta / chemistry. Aorta / embryology. Carbon Tetrachloride / adverse effects. Cisplatin / adverse effects. Drug-Induced Liver Injury. Immunohistochemistry. Kidney Diseases / chemically induced. Kidney Diseases / metabolism. Kidney Diseases / pathology. Liver / chemistry. Liver / embryology. Liver Diseases / metabolism. Liver Diseases / pathology. Lung / chemistry. Lung / embryology. Lung / ultrastructure. Mice. Mice, Inbred BALB C. Microscopy, Immunoelectron. Rats. Rats, Inbred F344. Spinal Cord / chemistry. Spinal Cord / embryology. Tumor Cells, Cultured / immunology. Tumor Cells, Cultured / metabolism. Tumor Cells, Cultured / ultrastructure

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBON TETRACHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Harcourt Publishers Ltd.